boron group element atom - Ontology Report

BD4 increases expression of Nphs1 mRNA in podocytes

RGD

PMID:22125642

RGD:40902998

NCBI chr 7:30,157,259...30,188,048
Ensembl chr 7:30,157,740...30,186,648

Synpo

synaptopodin

increases expression

BD4 increases expression of Synpo mRNA in podocytes

RGD

PMID:22125642

RGD:40902998

NCBI chr18:60,727,053...60,793,241
Ensembl chr18:60,727,045...60,793,214

2-aminoethoxydiphenylborane

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

BCL2-associated X protein

multiple interactions

2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased expression of BAX protein]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

B cell leukemia/lymphoma 2

multiple interactions

2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

caspase 12

multiple interactions

2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP12 protein]

NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032

caspase 3

multiple interactions

2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

Cd28

CD28 antigen

multiple interactions

2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species]

PMID:14607919

NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518

Grm1

glutamate receptor, metabotropic 1

multiple interactions

2-aminoethoxydiphenylborane inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein]

PMID:14622174

NCBI chr10:10,561,803...10,958,126
Ensembl chr10:10,561,803...10,958,100

nuclear factor, erythroid derived 2, like 2

multiple interactions

2-aminoethoxydiphenylborane inhibits the reaction [bisphenol A results in increased expression of NFE2L2 protein]

PMID:33408296

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

4,4-difluoro-4-bora-3a,4a-diaza-s-indacene

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Abcb11

ATP-binding cassette, sub-family B member 11

affects transport

ABCB11 protein affects the transport of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene

PMID:12739759

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,960

aluminium atom

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

angiotensin I converting enzyme

decreases activity

Aluminum results in decreased activity of ACE protein

PMID:12008977

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

Ache

acetylcholinesterase

multiple interactions
decreases activity

[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium co-treated with Zinc] results in increased activity of ACHE protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in increased activity of ACHE protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA; Aluminum promotes the reaction [Lead results in decreased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Copper inhibits the reaction [Aluminum results in decreased activity of ACHE protein]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of ACHE protein]

PMID:15266904 PMID:23354609 PMID:24486960 PMID:29170048 PMID:37415728

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

Acly

ATP citrate lyase

multiple interactions

Aluminum results in increased expression of and results in increased activity of ACLY protein

NCBI chr11:100,367,178...100,418,826
Ensembl chr11:100,367,179...100,418,826

Aco1

aconitase 1

decreases activity

Aluminum results in decreased activity of ACO1 protein

PMID:10806405

NCBI chr 4:40,143,265...40,199,009
Ensembl chr 4:40,143,081...40,198,338

Aco2

aconitase 2, mitochondrial

decreases activity
multiple interactions

Aluminum results in decreased activity of ACO2 protein
Aluminum promotes the reaction [Nitroprusside results in decreased activity of ACO2 protein]
Aluminum results in decreased expression of and results in decreased activity of ACO2 protein

PMID:12470706 PMID:16906525 PMID:19010380

NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334

Alb

albumin

affects binding

ALB protein binds to Aluminum

PMID:14507469

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

Alox5

arachidonate 5-lipoxygenase

multiple interactions
increases expression

caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein]
Aluminum results in increased expression of ALOX5 mRNA; Aluminum results in increased expression of ALOX5 protein

PMID:27368151

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

Alpl

alkaline phosphatase, liver/bone/kidney

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of ALPL mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of ALPL mRNA]

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

Apob

apolipoprotein B

increases expression

Aluminum results in increased expression of APOB protein

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

App

amyloid beta precursor protein

affects binding
multiple interactions
increases expression
increases cleavage

APP protein binds to Aluminum
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA]
[APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA
Aluminum results in increased expression of APP mRNA
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in increased expression of APP protein]; Vitamin E inhibits the reaction [Aluminum results in increased cleavage of APP protein]

PMID:12039845 PMID:16308480 PMID:16724269 PMID:16928369 PMID:16942756 More...

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

Atxn3

ataxin 3

affects folding
multiple interactions

Aluminum affects the folding of ATXN3 protein polymorphism
Aluminum promotes the reaction [ATXN3 protein polymorphism binds to ATXN3 protein polymorphism]

PMID:17300980

NCBI chr12:101,885,160...101,928,139
Ensembl chr12:101,885,160...101,924,505

BCL2-associated X protein

affects response to substance
multiple interactions

BAX protein affects the susceptibility to Aluminum
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX protein]
[aluminum chlorhydrate results in increased abundance of Aluminum] which affects the expression of BAX protein

PMID:20385067 PMID:31945389 PMID:34547296

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

Bbox1

gamma-butyrobetaine hydroxylase 1

multiple interactions
decreases expression

Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]
Aluminum results in decreased expression of BBOX1 protein

PMID:21439360

NCBI chr 2:110,094,401...110,145,158
Ensembl chr 2:110,093,042...110,144,905

B cell leukemia/lymphoma 2

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein]
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein]

PMID:31945389 PMID:34547296

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

BCL2-like 1

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2L1 protein

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

bone gamma carboxyglutamate protein

multiple interactions
decreases secretion

Aluminum inhibits the reaction [Calcitriol results in increased secretion of BGLAP protein]; Calcitriol inhibits the reaction [Aluminum results in decreased secretion of BGLAP protein]
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP protein]

PMID:9626627 PMID:34547296

NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771

caspase 12

multiple interactions

[aluminum chloride results in increased abundance of Aluminum] which results in increased expression of CASP12 mRNA

NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032

caspase 3

increases expression
multiple interactions

Aluminum results in increased expression of CASP3
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of CASP3 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased cleavage of CASP3 protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CASP3 mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased cleavage of CASP3 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CASP3 mRNA]

PMID:21972528 PMID:34547296 PMID:37415728

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

Casp9

caspase 9

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein]

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

Casr

calcium-sensing receptor

multiple interactions

[Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein

PMID:10231437

NCBI chr16:36,310,947...36,382,605
Ensembl chr16:36,314,058...36,382,503

catalase

decreases activity
multiple interactions

Aluminum results in decreased activity of CAT protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased activity of CAT protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased activity of CAT protein]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in decreased activity of CAT protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased activity of CAT protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased activity of CAT protein; CAT protein results in decreased susceptibility to [Tyramine co-treated with Aluminum]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of CAT protein]
Vitamin E inhibits the reaction [Aluminum results in decreased activity of CAT protein]

PMID:15526171 PMID:17709913 PMID:24486960 PMID:34547296 PMID:37415728

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

Cdh1

cadherin 1

multiple interactions

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

Chat

choline acetyltransferase

decreases expression
decreases activity
multiple interactions

Aluminum results in decreased expression of CHAT protein
Aluminum results in decreased activity of CHAT protein
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in decreased expression of CHAT protein]

PMID:16724269 PMID:16928369

NCBI chr14:32,130,160...32,187,866
Ensembl chr14:32,130,160...32,187,946

collagen, type I, alpha 1

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of COL1A1 mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of COL1A1 mRNA]

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

Crp

C-reactive protein, pentraxin-related

multiple interactions

[Zinc co-treated with Aluminum] results in increased expression of CRP protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of CRP protein

PMID:27816692

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

C-X-C motif chemokine ligand 15

increases expression

Aluminum analog results in increased expression of CXCL8 mRNA

PMID:23724284

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

Cycs

cytochrome c, somatic

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CYCS mRNA]

NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518

Daxx

Fas death domain-associated protein

increases expression

Aluminum results in increased expression of DAXX mRNA

PMID:16308480

NCBI chr17:34,128,379...34,134,564
Ensembl chr17:34,128,388...34,134,564

Drd1

dopamine receptor D1

multiple interactions

Aluminum inhibits the reaction [SCH 23390 binds to DRD1 protein]

NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724

Drd2

dopamine receptor D2

multiple interactions

Aluminum inhibits the reaction [3-N-methylspiperone binds to DRD2 protein]

NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477

Eno2

enolase 2, gamma neuronal

decreases activity

Aluminum results in decreased activity of ENO2 protein

PMID:11860913

NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636

Epor

erythropoietin receptor

affects expression

Aluminum affects the expression of EPOR protein

PMID:15777837

NCBI chr 9:21,870,193...21,874,915
Ensembl chr 9:21,870,193...21,874,802

Esr1

estrogen receptor 1 (alpha)

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [Estradiol results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in increased expression of ESR1 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in increased expression of ESR1 protein

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

Esr2

estrogen receptor 2 (beta)

multiple interactions

[[aluminum chlorhydrate results in increased abundance of Aluminum] co-treated with [Tretinoin co-treated with Estradiol]] affects the localization of ESR2 protein; [[aluminum chlorhydrate results in increased abundance of Aluminum] which co-treated with Tretinoin] results in decreased expression of and affects the localization of ESR2 protein; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of and affects the localization of ESR2 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in decreased expression of ESR2 protein

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

coagulation factor VIII

affects folding
multiple interactions

Aluminum affects the folding of F8 protein
[Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein

PMID:15349964

NCBI chr X:74,213,950...74,426,342
Ensembl chr X:74,216,321...74,426,221

Fh1

fumarate hydratase 1

multiple interactions

Aluminum results in decreased expression of and results in decreased activity of FH protein

PMID:16906525

NCBI chr 1:175,428,944...175,453,201
Ensembl chr 1:175,427,940...175,453,201

Fos

FBJ osteosarcoma oncogene

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein]

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G6pdx

glucose-6-phosphate dehydrogenase X-linked

increases activity

Aluminum results in increased activity of G6PD protein

PMID:16572710 PMID:16979867

NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800

Gfap

glial fibrillary acidic protein

increases expression
multiple interactions

Aluminum results in increased expression of GFAP protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of GFAP protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of GFAP protein]

PMID:16545059 PMID:31363819

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

Gnai1

G protein subunit alpha i1

decreases expression

Aluminum results in decreased expression of GNAI1 protein

NCBI chr 5:18,470,133...18,565,411
Ensembl chr 5:18,470,133...18,565,353

Gnai2

G protein subunit alpha i2

decreases expression

Aluminum results in decreased expression of GNAI2 protein

NCBI chr 9:107,491,324...107,512,542
Ensembl chr 9:107,491,324...107,512,566

Gnaq

guanine nucleotide binding protein, alpha q polypeptide

increases response to substance

GNAQ protein results in increased susceptibility to Aluminum

PMID:15068510

NCBI chr19:16,110,048...16,365,884
Ensembl chr19:16,110,195...16,364,827

Gpd1

glycerol-3-phosphate dehydrogenase 1 (soluble)

multiple interactions

Aluminum results in increased expression of and results in increased activity of GPD1 protein

NCBI chr15:99,615,468...99,622,895
Ensembl chr15:99,615,396...99,622,886

Gpx1

glutathione peroxidase 1

decreases activity
multiple interactions

Aluminum results in decreased activity of GPX1 protein
Vitamin E inhibits the reaction [Aluminum results in decreased activity of GPX1 protein]

PMID:17709913

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

Gsr

glutathione reductase

decreases expression
multiple interactions

Aluminum results in decreased expression of GSR protein
Plant Extracts inhibits the reaction [Aluminum results in decreased expression of GSR protein]

PMID:24486960

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

Hif1a

hypoxia inducible factor 1, alpha subunit

increases localization

Aluminum results in increased localization of HIF1A protein

NCBI chr12:73,948,098...73,994,328
Ensembl chr12:73,948,149...73,994,304

Hk1

hexokinase 1

multiple interactions
decreases activity

Meclofenoxate inhibits the reaction [Aluminum results in decreased activity of HK1 protein]

PMID:16969689

NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687

Idh1

isocitrate dehydrogenase 1 (NADP+), soluble

decreases activity

Aluminum results in decreased activity of IDH1 protein

NCBI chr 1:65,197,775...65,225,638
Ensembl chr 1:65,197,775...65,225,659

Idh2

isocitrate dehydrogenase 2 (NADP+), mitochondrial

decreases activity

Aluminum results in decreased activity of IDH2 protein

NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140

Ifnb1

interferon beta 1, fibroblast

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IFNB1 mRNA]

NCBI chr 4:88,440,253...88,441,083
Ensembl chr 4:88,440,262...88,441,011

insulin-like growth factor 1

multiple interactions

Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]

PMID:14745455

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

Il12b

interleukin 12b

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL12B mRNA]

NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860

interleukin 1 beta

multiple interactions
increases expression

[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of IL1B protein]

PMID:16545059 PMID:27368151 PMID:29170048

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

interleukin 4

increases expression

Aluminum results in increased expression of IL4 mRNA

PMID:16630673

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

interleukin 6

multiple interactions
increases expression

[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of IL6 protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein]
[Zinc co-treated with Aluminum] results in increased expression of IL6 protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of IL6 protein

PMID:27368151 PMID:27816692 PMID:29170048 PMID:37415728

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

Jun

jun proto-oncogene

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein]

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

Klk1

kallikrein 1

multiple interactions

Aluminum binds to and results in decreased activity of KLK1 protein

PMID:15558947

NCBI chr 7:43,874,784...43,879,046
Ensembl chr 7:43,874,784...43,879,042

Litaf

LPS-induced TN factor

multiple interactions

[Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of LITAF mRNA

PMID:17408380

NCBI chr16:10,777,137...10,810,985
Ensembl chr16:10,777,139...10,884,021

Lonrf2

LON peptidase N-terminal domain and ring finger 2

decreases expression

Aluminum results in decreased expression of LONRF2 mRNA

NCBI chr 1:38,832,750...38,875,768
Ensembl chr 1:38,832,726...38,875,792

Map1lc3b

microtubule-associated protein 1 light chain 3 beta

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MAP1LC3B mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased lipidation of MAP1LC3B protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MAP1LC3B mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased lipidation of MAP1LC3B protein]

NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499

Mapk3

mitogen-activated protein kinase 3

multiple interactions

[Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein

PMID:16728372

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

Mapt

microtubule-associated protein tau

increases phosphorylation
multiple interactions

Aluminum results in increased phosphorylation of MAPT protein
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]

PMID:17662457 PMID:29170048

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

Mir21a

microRNA 21a

multiple interactions

[Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR21 mRNA

NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984

Mir30d

microRNA 30d

multiple interactions

[Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR30D mRNA

NCBI chr15:68,213,057...68,213,138
Ensembl chr15:68,213,057...68,213,138

Mir322

microRNA 322

multiple interactions

[Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR424 mRNA

NCBI chr X:52,143,132...52,143,226
Ensembl chr X:52,143,132...52,143,226

matrix metallopeptidase 2

increases expression

Aluminum results in increased expression of MMP2 protein

PMID:16052892

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

Mmp7

matrix metallopeptidase 7

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP7 mRNA

NCBI chr 9:7,692,091...7,699,586
Ensembl chr 9:7,692,091...7,699,586

Mmp9

matrix metallopeptidase 9

increases expression
multiple interactions

Aluminum results in increased expression of MMP9 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP9 mRNA

PMID:16052892 PMID:32437896

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

Mpo

myeloperoxidase

increases expression

Aluminum results in increased expression of MPO protein

PMID:17402216

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

Mtr

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions

Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]; Aluminum inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]

PMID:14745455 PMID:26989453

NCBI chr13:12,196,217...12,273,090
Ensembl chr13:12,197,598...12,272,999

nuclear factor, erythroid derived 2, like 2

multiple interactions

[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in decreased expression of NFE2L2 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased expression of NFE2L2 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased expression of NFE2L2 protein

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions

[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased expression of NFKB1 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased expression of NFKB1 protein

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

Nos2

nitric oxide synthase 2, inducible

multiple interactions

[Aluminum co-treated with Iron] results in increased expression of NOS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]

PMID:16728372 PMID:23690655

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

Nrg1

neuregulin 1

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]

NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825
Ensembl chr 8:32,304,579...33,374,825

Ogdh

oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)

multiple interactions
increases activity

Aluminum results in decreased expression of and results in decreased activity of OGDH protein
Aluminum results in increased activity of OGDH protein

PMID:10806405 PMID:16906525

NCBI chr11:6,241,597...6,309,094
Ensembl chr11:6,241,633...6,306,642

Oprd1

opioid receptor, delta 1

multiple interactions

[Enkephalin, D-Penicillamine (2,5)- binds to and results in increased activity of OPRD1 protein] which results in decreased abundance of Aluminum

PMID:7477890

NCBI chr 4:131,834,980...131,872,042
Ensembl chr 4:131,838,037...131,871,797

Pck1

phosphoenolpyruvate carboxykinase 1, cytosolic

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of PCK1 protein

NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066

proliferating cell nuclear antigen

multiple interactions

[aluminum chloride results in increased abundance of Aluminum] which results in decreased expression of PCNA mRNA

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

Pink1

PTEN induced putative kinase 1

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 mRNA]

NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618

Pklr

pyruvate kinase liver and red blood cell

increases activity

Aluminum results in increased activity of PKLR protein

NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091

Plcd1

phospholipase C, delta 1

increases expression

Aluminum results in increased expression of PLCD1 protein

PMID:10814511

NCBI chr 9:118,900,595...118,922,570
Ensembl chr 9:118,900,595...118,922,570

Prkn

parkin RBR E3 ubiquitin protein ligase

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN mRNA]

NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

Aluminum results in increased expression of PTGS2 mRNA; Aluminum results in increased expression of PTGS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 protein]

PMID:16928369 PMID:23690655

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

Pth

parathyroid hormone

multiple interactions

[TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein

PMID:10978387

NCBI chr 7:112,984,783...112,987,879
Ensembl chr 7:112,984,787...112,987,777

Rcvrn

recoverin

multiple interactions

[APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA

PMID:21298039

NCBI chr11:67,586,152...67,594,181
Ensembl chr11:67,586,152...67,594,159

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

Rpl37

ribosomal protein L37

decreases expression

Aluminum results in decreased expression of RPL37 mRNA; Aluminum results in decreased expression of RPL37 protein

NCBI chr15:5,146,127...5,148,626
Ensembl chr15:5,146,127...5,148,622

S100b

S100 protein, beta polypeptide, neural

increases expression
multiple interactions

Aluminum results in increased expression of S100B protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of S100B protein]

PMID:16545059

NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993

Scgb1a1

secretoglobin, family 1A, member 1

decreases expression

Aluminum results in decreased expression of SCGB1A1 protein

PMID:16052892 PMID:16099050

NCBI chr19:9,061,006...9,065,320
Ensembl chr19:9,061,000...9,065,322

Slc2a1

solute carrier family 2 (facilitated glucose transporter), member 1

increases expression

Aluminum results in increased expression of SLC2A1 protein

NCBI chr 4:118,965,942...118,994,527
Ensembl chr 4:118,965,908...118,995,180

Snai1

snail family zinc finger 1

multiple interactions

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein

NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734

Snca

synuclein, alpha

affects response to substance

SNCA protein affects the susceptibility to Aluminum

PMID:23106139

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

Sod2

superoxide dismutase 2, mitochondrial

decreases activity

Aluminum results in decreased activity of SOD2 protein

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

Sqstm1

sequestosome 1

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 mRNA]

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

Tfrc

transferrin receptor

decreases expression
affects uptake

Aluminum results in decreased expression of TFRC mRNA
TFRC protein affects the uptake of Aluminum

PMID:9630424 PMID:11068183

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

transforming growth factor, beta 1

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of TGFB1 mRNA

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

tumor necrosis factor

increases expression
multiple interactions

Aluminum results in increased expression of TNF protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of TNF protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of TNF protein]
[Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of TNF mRNA

PMID:16545059 PMID:17408380 PMID:23690655 PMID:27368151 PMID:29170048 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

Trf

transferrin

multiple interactions
increases uptake
affects binding

[Aluminum binds to TF protein] which results in decreased uptake of Iron; [Aluminum binds to TF protein] which results in decreased uptake of Manganese; [Aluminum binds to TF protein] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] which results in increased uptake of Iron; [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and results in increased uptake of Aluminum
TF protein results in increased uptake of Aluminum
Aluminum binds to TF protein; TF protein binds to Aluminum
TRF protein binds to Aluminum

PMID:1375080 PMID:2039817 PMID:2308257 PMID:8782865 PMID:10978387 More...

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

Tubb3

tubulin, beta 3 class III

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of TUBB3 protein

PMID:31363819

NCBI chr 8:124,138,292...124,148,754
Ensembl chr 8:124,138,163...124,148,754

Txn2

thioredoxin 2

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of TXN2 protein

NCBI chr15:77,799,251...77,813,194
Ensembl chr15:77,799,247...77,813,206

Uba52

ubiquitin A-52 residue ribosomal protein fusion product 1

decreases expression

Aluminum results in decreased expression of UBA52 mRNA; Aluminum results in decreased expression of UBA52 protein

NCBI chr 8:70,960,913...70,963,067
Ensembl chr 8:70,960,913...70,963,451

Vegfa

vascular endothelial growth factor A

multiple interactions

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VEGFA protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of and results in increased secretion of VEGFA protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased secretion of VEGFA protein

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

Vim

vimentin

multiple interactions

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein

NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637

Xdh

xanthine dehydrogenase

increases activity

Aluminum results in increased activity of XDH protein

PMID:11787993

NCBI chr17:74,190,890...74,257,369
Ensembl chr17:74,190,890...74,257,191

aluminium hydroxide

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Abcc2

ATP-binding cassette, sub-family member 2

decreases expression

Aluminum Hydroxide results in decreased expression of ABCC2 protein

PMID:14976346

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

Acta2

actin alpha 2, smooth muscle, aorta

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein]

NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990

Akt1

thymoma viral proto-oncogene 1

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

Casp1

caspase 1

multiple interactions

[Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:18604214 PMID:22075093

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

catalase

decreases activity

Aluminum Hydroxide results in decreased activity of CAT protein

PMID:14976346

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

Ccl2

C-C motif chemokine ligand 2

increases secretion

Aluminum Hydroxide results in increased secretion of CCL2 protein

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

Ccl3

C-C motif chemokine ligand 3

increases secretion

Aluminum Hydroxide results in increased secretion of CCL3 protein

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

Ccl4

C-C motif chemokine ligand 4

increases secretion

Aluminum Hydroxide results in increased secretion of CCL4 protein

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

Ccl5

C-C motif chemokine ligand 5

increases secretion

Aluminum Hydroxide results in increased secretion of CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

Ccr7

C-C motif chemokine receptor 7

multiple interactions

Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

Cd14

CD14 antigen

decreases expression

Aluminum Hydroxide results in decreased expression of CD14 protein

NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851

Cd4

CD4 antigen

affects response to substance

CD4 protein affects the susceptibility to Aluminum Hydroxide

NCBI chr 6:124,841,656...124,865,210
Ensembl chr 6:124,841,655...124,865,184

Cd40

CD40 antigen

increases expression

Aluminum Hydroxide results in increased expression of CD40 protein

NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868

Cd80

CD80 antigen

multiple interactions

Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]

NCBI chr16:38,277,793...38,316,682
Ensembl chr16:38,275,923...38,316,697

Cd83

CD83 antigen

increases expression

Aluminum Hydroxide results in increased expression of CD83 protein

NCBI chr13:43,938,588...43,956,609
Ensembl chr13:43,938,251...43,956,608

Cd86

CD86 antigen

increases expression
multiple interactions

Aluminum Hydroxide results in increased expression of CD86 protein
Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein]

PMID:11160013 PMID:18390722

NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443

Chrna4

cholinergic receptor, nicotinic, alpha polypeptide 4

multiple interactions

Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]

PMID:22750351

NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339

Chrnb2

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]

PMID:22750351

NCBI chr 3:89,660,755...89,671,939
Ensembl chr 3:89,653,502...89,671,939

Crlf2

cytokine receptor-like factor 2

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 mRNA]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 protein]

NCBI chr 5:109,702,575...109,707,301
Ensembl chr 5:109,702,575...109,706,859

Csf2

colony stimulating factor 2 (granulocyte-macrophage)

multiple interactions

Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]; Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein]

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

Cxcl10

C-X-C motif chemokine ligand 10

multiple interactions

[Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein]

PMID:17404311

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

C-X-C motif chemokine ligand 15

increases secretion

Aluminum Hydroxide results in increased secretion of CXCL8 protein

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

Gata3

GATA binding protein 3

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of GATA3 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of GATA3 mRNA]

NCBI chr 2:9,861,889...9,894,845
Ensembl chr 2:9,861,889...9,894,845

Icam1

intercellular adhesion molecule 1

increases expression

Aluminum Hydroxide results in increased expression of ICAM1 protein

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

Il13

interleukin 13

increases expression
multiple interactions

Aluminum Hydroxide results in increased expression of IL13 mRNA
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein]

PMID:9328138 PMID:35481609 PMID:36029577

NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529

interleukin 1 beta

multiple interactions

[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein]
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:17404311 PMID:18604214 PMID:22075093

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

Il1r1

interleukin 1 receptor, type I

multiple interactions

IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:18604214

NCBI chr 1:40,261,651...40,355,361
Ensembl chr 1:40,264,240...40,356,417

Il1rn

interleukin 1 receptor antagonist

increases secretion

Aluminum Hydroxide results in increased secretion of IL1RN protein

NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506

Il2

interleukin 2

increases expression
multiple interactions

Aluminum Hydroxide results in increased expression of IL2 mRNA
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]

PMID:9328138 PMID:22075093

NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108

interleukin 4

increases expression
multiple interactions
affects response to substance

Aluminum Hydroxide results in increased expression of IL4 mRNA
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein]
IL4 protein affects the susceptibility to Aluminum Hydroxide
Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]

PMID:9328138 PMID:11160013 PMID:18390722 PMID:35481609 PMID:36029577

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

Il5

interleukin 5

increases expression
multiple interactions

Aluminum Hydroxide results in increased expression of IL5 mRNA
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]

PMID:9328138 PMID:35481609 PMID:36029577

NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933

interleukin 6

increases expression

Aluminum Hydroxide results in increased expression of IL6 mRNA

PMID:9328138

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

Il7r

interleukin 7 receptor

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R mRNA]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R protein]

NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262

Jak1

Janus kinase 1

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK1 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK1 protein]

NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479

Jak2

Janus kinase 2

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK2 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK2 protein]

NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480

Muc5ac

mucin 5, subtypes A and C, tracheobronchial/gastric

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA]

NCBI chr 7:141,342,695...141,372,964
Ensembl chr 7:141,342,709...141,372,968

Nlrp3

NLR family, pyrin domain containing 3

multiple interactions

NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:18604214

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

Pycard

PYD and CARD domain containing

multiple interactions

PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:18604214

NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039

Stat3

signal transducer and activator of transcription 3

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of STAT3 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of STAT3 protein]

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

Tfrc

transferrin receptor

multiple interactions

Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

transforming growth factor, beta 1

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

Tlr4

toll-like receptor 4

multiple interactions

TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide]

PMID:22075093

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

tumor necrosis factor

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

Tnfrsf4

tumor necrosis factor receptor superfamily, member 4

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFRSF4 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFRSF4 mRNA]

NCBI chr 4:156,098,049...156,101,070
Ensembl chr 4:156,098,300...156,101,069

Tnfsf4

tumor necrosis factor (ligand) superfamily, member 4

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFSF4 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFSF4 mRNA]

NCBI chr 1:161,223,009...161,245,777
Ensembl chr 1:161,222,980...161,245,981

Tslp

thymic stromal lymphopoietin

multiple interactions

[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP protein]

NCBI chr18:32,948,436...32,952,852
Ensembl chr18:32,948,436...32,952,850

aluminium ion

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Hmbs

hydroxymethylbilane synthase

decreases activity

Aluminium ion decreases activity of purified Hmbs protein

RGD

PMID:6732900

RGD:25394584

NCBI chr 9:44,247,645...44,255,525
Ensembl chr 9:44,247,636...44,255,525

aluminium oxide

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Acp5

acid phosphatase 5, tartrate resistant

decreases expression

Aluminum Oxide results in decreased expression of ACP5 mRNA

PMID:15585240

NCBI chr 9:22,038,023...22,047,042
Ensembl chr 9:22,038,023...22,047,007

Actr2

ARP2 actin-related protein 2

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of ACTR2 protein

NCBI chr11:20,012,304...20,062,951
Ensembl chr11:20,012,304...20,062,913

Alpl

alkaline phosphatase, liver/bone/kidney

increases expression

Aluminum Oxide results in increased expression of ALPL mRNA

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

BCL2-like 1

increases expression

Aluminum Oxide analog results in increased expression of BCL2L1 mRNA

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

bone gamma carboxyglutamate protein

increases expression

Aluminum Oxide results in increased expression of BGLAP mRNA

NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771

Bgn

biglycan

increases expression

Aluminum Oxide results in increased expression of BGN mRNA

NCBI chr X:72,527,207...72,539,542
Ensembl chr X:72,527,208...72,539,539

Bmp1

bone morphogenetic protein 1

increases expression

Aluminum Oxide results in increased expression of BMP1 mRNA

NCBI chr14:70,711,995...70,758,280
Ensembl chr14:70,711,998...70,757,674

Bmp2

bone morphogenetic protein 2

increases expression

Aluminum Oxide results in increased expression of BMP2 mRNA

NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805

Bmp4

bone morphogenetic protein 4

increases expression

Aluminum Oxide results in increased expression of BMP4 mRNA

NCBI chr14:46,620,982...46,628,126
Ensembl chr14:46,620,977...46,628,126

Bmp6

bone morphogenetic protein 6

decreases expression

Aluminum Oxide results in decreased expression of BMP6 mRNA

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

complement component 3

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of C3 protein

NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136

Camp

cathelicidin antimicrobial peptide

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CAMP protein

NCBI chr 9:109,676,445...109,678,524
Ensembl chr 9:109,676,447...109,678,685

caspase 3

increases expression
multiple interactions

Aluminum Oxide results in increased expression of CASP3
Aluminum Oxide results in increased expression of CASP3 mRNA
sesamol inhibits the reaction [Aluminum Oxide results in increased expression of CASP3 mRNA]

PMID:21329562 PMID:35403826

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

catalase

decreases activity
multiple interactions

Aluminum Oxide results in decreased activity of CAT protein
sesamol inhibits the reaction [Aluminum Oxide results in decreased activity of CAT protein]

PMID:35403826

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

Ccl2

C-C motif chemokine ligand 2

increases secretion

Aluminum Oxide results in increased secretion of CCL2 protein

PMID:17618502

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

Cd14

CD14 antigen

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CD14 protein

NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851

Cd36

CD36 molecule

increases expression

Aluminum Oxide results in increased expression of CD36 mRNA

NCBI chr 5:17,986,688...18,093,957
Ensembl chr 5:17,986,688...18,093,799

Cdh11

cadherin 11

increases expression

Aluminum Oxide results in increased expression of CDH11 mRNA

NCBI chr 8:103,358,727...103,512,125
Ensembl chr 8:103,358,727...103,512,274

Cdkn1a

cyclin dependent kinase inhibitor 1A

increases expression

Aluminum Oxide analog results in increased expression of CDKN1A mRNA

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

Clu

clusterin

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CLU protein

NCBI chr14:66,205,932...66,218,997
Ensembl chr14:66,205,932...66,218,996

Col10a1

collagen, type X, alpha 1

increases expression

Aluminum Oxide results in increased expression of COL10A1 mRNA

NCBI chr10:34,265,977...34,273,081
Ensembl chr10:34,265,977...34,273,081

Col11a1

collagen, type XI, alpha 1

increases expression

Aluminum Oxide results in increased expression of COL11A1 mRNA

NCBI chr 3:113,823,933...114,014,405
Ensembl chr 3:113,824,189...114,014,367

Col15a1

collagen, type XV, alpha 1

increases expression

Aluminum Oxide results in increased expression of COL15A1 mRNA

NCBI chr 4:47,207,744...47,313,165
Ensembl chr 4:47,208,161...47,313,167

collagen, type I, alpha 1

multiple interactions

[Aluminum Oxide co-treated with Magnesium] results in increased expression of COL1A1 protein

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

Col1a2

collagen, type I, alpha 2

increases expression

Aluminum Oxide results in increased expression of COL1A2 mRNA

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

Comp

cartilage oligomeric matrix protein

increases expression

Aluminum Oxide results in increased expression of COMP mRNA

NCBI chr 8:70,826,186...70,834,721
Ensembl chr 8:70,826,208...70,834,716

Csf2

colony stimulating factor 2 (granulocyte-macrophage)

increases secretion

Aluminum Oxide results in increased secretion of CSF2 protein

PMID:15046894

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

Ctsk

cathepsin K

increases expression

Aluminum Oxide results in increased expression of CTSK mRNA

NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673

C-X-C motif chemokine ligand 15

increases expression

Aluminum Oxide results in increased expression of CXCL8 mRNA

PMID:15183442

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

Egfr

epidermal growth factor receptor

increases expression

Aluminum Oxide results in increased expression of EGFR mRNA

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

Fgb

fibrinogen beta chain

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of FGB protein

NCBI chr 3:82,949,553...82,957,170
Ensembl chr 3:82,947,448...82,957,170

Flt1

FMS-like tyrosine kinase 1

increases expression

Aluminum Oxide results in increased expression of FLT1 mRNA

NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821

Fn1

fibronectin 1

increases expression

Aluminum Oxide results in increased expression of FN1 mRNA

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

Fos

FBJ osteosarcoma oncogene

decreases expression

Aluminum Oxide results in decreased expression of FOS mRNA

PMID:15585240

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

Ibsp

integrin binding sialoprotein

increases expression

Aluminum Oxide results in increased expression of IBSP mRNA

NCBI chr 5:104,447,153...104,459,338
Ensembl chr 5:104,447,037...104,459,335

Icam1

intercellular adhesion molecule 1

increases expression

Aluminum Oxide results in increased expression of ICAM1 protein

PMID:18456438

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

insulin-like growth factor 1

affects expression

Aluminum Oxide affects the expression of IGF1 mRNA

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

Il10

interleukin 10

increases expression

Aluminum Oxide results in increased expression of IL10 mRNA

PMID:15183442

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

Il1a

interleukin 1 alpha

increases expression

Aluminum Oxide results in increased expression of IL1A mRNA

PMID:15183442

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

interleukin 1 beta

increases expression
increases secretion
multiple interactions

Aluminum Oxide results in increased expression of IL1B mRNA
Aluminum Oxide results in increased secretion of IL1B protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in decreased secretion of IL1B protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]
[Aluminum Oxide co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon] promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]

PMID:15183442 PMID:16488289 PMID:17618502 PMID:25216247

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

interleukin 6

increases expression
multiple interactions
decreases secretion

Aluminum Oxide results in increased expression of IL6 mRNA; Aluminum Oxide results in increased expression of IL6 protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of IL6 protein
Aluminum Oxide results in decreased secretion of IL6 protein
Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL6 protein]

PMID:11771709 PMID:25216247

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

Itga1

integrin alpha 1

increases expression

Aluminum Oxide results in increased expression of ITGA1 mRNA

NCBI chr13:115,094,615...115,238,500
Ensembl chr13:115,089,632...115,238,500

Itga3

integrin alpha 3

increases expression

Aluminum Oxide results in increased expression of ITGA3 mRNA

NCBI chr11:94,935,301...94,967,637
Ensembl chr11:94,935,300...94,967,627

Itga5

integrin alpha 5 (fibronectin receptor alpha)

multiple interactions

[Aluminum Oxide co-treated with Magnesium] results in increased expression of ITGA5 protein

NCBI chr15:103,252,713...103,275,218
Ensembl chr15:103,252,713...103,275,190

Itgb1

integrin beta 1 (fibronectin receptor beta)

multiple interactions

[Aluminum Oxide co-treated with Magnesium] results in increased expression of ITGB1 protein

NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681

Itih4

inter alpha-trypsin inhibitor, heavy chain 4

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of ITIH4 protein

NCBI chr14:30,608,433...30,623,943
Ensembl chr14:30,608,433...30,624,310

Jun

jun proto-oncogene

increases expression

Aluminum Oxide results in increased expression of JUN mRNA

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

Klk1b16

kallikrein 1-related peptidase b16

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of KLK1B16 protein

NCBI chr 7:43,771,678...43,791,034
Ensembl chr 7:43,786,191...43,791,034

Lcn2

lipocalin 2

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of LCN2 protein

NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264

Ltf

lactotransferrin

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of LTF protein

NCBI chr 9:110,848,360...110,871,834
Ensembl chr 9:110,848,339...110,871,835

Mmp1b

matrix metallopeptidase 1b (interstitial collagenase)

increases expression

Aluminum Oxide results in increased expression of MMP1 mRNA

NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047

matrix metallopeptidase 2

increases expression

Aluminum Oxide results in increased expression of MMP2 mRNA

PMID:14661256

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

Mmp3

matrix metallopeptidase 3

increases expression

Aluminum Oxide results in increased expression of MMP3 mRNA

NCBI chr 9:7,445,822...7,455,975
Ensembl chr 9:7,445,822...7,455,975

Mmp8

matrix metallopeptidase 8

decreases expression

Aluminum Oxide results in decreased expression of MMP8 mRNA

NCBI chr 9:7,558,430...7,568,487
Ensembl chr 9:7,558,457...7,568,486

Mmp9

matrix metallopeptidase 9

increases expression

Aluminum Oxide results in increased expression of MMP9 mRNA

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

Mpo

myeloperoxidase

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of MPO protein

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

Pdgfa

platelet derived growth factor, alpha

increases expression

Aluminum Oxide results in increased expression of PDGFA mRNA

NCBI chr 5:138,961,769...138,986,336
Ensembl chr 5:138,961,769...138,983,125

Phex

phosphate regulating endopeptidase homolog, X-linked

increases expression

Aluminum Oxide results in increased expression of PHEX mRNA

NCBI chr X:155,945,071...156,198,282
Ensembl chr X:155,945,071...156,198,308

Ptk2

PTK2 protein tyrosine kinase 2

multiple interactions

[Aluminum Oxide co-treated with Magnesium] results in increased expression of PTK2 protein

NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129

S100a8

S100 calcium binding protein A8 (calgranulin A)

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of S100A8 protein

NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342

S100a9

S100 calcium binding protein A9 (calgranulin B)

multiple interactions

[Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of S100A9 protein

NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028

Scarb1

scavenger receptor class B, member 1

decreases expression

Aluminum Oxide results in decreased expression of SCARB1 mRNA

NCBI chr 5:125,354,151...125,418,158
Ensembl chr 5:125,354,151...125,418,158

Sele

selectin, endothelial cell

increases expression

Aluminum Oxide results in increased expression of SELE protein

PMID:18456438

NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246

Serpinh1

serine (or cysteine) peptidase inhibitor, clade H, member 1

increases expression

Aluminum Oxide results in increased expression of SERPINH1 mRNA

NCBI chr 7:98,994,583...99,002,321
Ensembl chr 7:98,994,583...99,002,446

Shc1

src homology 2 domain-containing transforming protein C1

multiple interactions

[Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein; [Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein alternative form

NCBI chr 3:89,325,858...89,337,336
Ensembl chr 3:89,325,750...89,337,334

Sod1

superoxide dismutase 1, soluble

decreases activity
multiple interactions

Aluminum Oxide results in decreased activity of SOD1 protein
sesamol inhibits the reaction [Aluminum Oxide results in decreased activity of SOD1 protein]

PMID:35403826

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

Sp7

Sp7 transcription factor 7

increases expression

Aluminum Oxide results in increased expression of SP7 mRNA

NCBI chr15:102,265,038...102,275,498
Ensembl chr15:102,265,041...102,275,617

Spp1

secreted phosphoprotein 1

increases expression
multiple interactions
decreases secretion

Aluminum Oxide results in increased expression of SPP1 mRNA
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of SPP1 protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased expression of SPP1 mRNA]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]
Aluminum Oxide results in decreased secretion of SPP1 protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]

PMID:19464052 PMID:25216247

NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916

transforming growth factor, beta 1

increases expression

Aluminum Oxide results in increased expression of TGFB1 mRNA

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

Tgfbr2

transforming growth factor, beta receptor II

increases expression

Aluminum Oxide results in increased expression of TGFBR2 mRNA

NCBI chr 9:115,916,763...116,004,431
Ensembl chr 9:115,913,361...116,004,428

tumor necrosis factor

increases activity
multiple interactions
increases expression
affects secretion

Aluminum Oxide results in increased activity of TNF protein
sesamol inhibits the reaction [Aluminum Oxide results in increased expression of TNF mRNA]
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased expression of TNF mRNA
Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of TNF protein]
Aluminum Oxide affects the secretion of TNF protein

PMID:10413987 PMID:11306444 PMID:15183442 PMID:16488289 PMID:25216247 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

Tnfsf10

tumor necrosis factor (ligand) superfamily, member 10

increases expression

Aluminum Oxide analog results in increased expression of TNFSF10 mRNA

NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576

Trp53

transformation related protein 53

increases expression

Aluminum Oxide analog results in increased expression of TP53 mRNA

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

Vcam1

vascular cell adhesion molecule 1

increases expression

Aluminum Oxide results in increased expression of VCAM1 mRNA; Aluminum Oxide results in increased expression of VCAM1 protein

PMID:18456438 PMID:19464052

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

Vegfa

vascular endothelial growth factor A

increases expression

Aluminum Oxide results in increased expression of VEGFA mRNA

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

Vegfb

vascular endothelial growth factor B

increases expression

Aluminum Oxide results in increased expression of VEGFB mRNA

NCBI chr19:6,959,840...6,965,019
Ensembl chr19:6,959,841...6,965,019

aluminium phosphide

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

catalase

decreases expression
decreases activity

aluminum phosphide results in decreased expression of CAT protein
aluminum phosphide results in decreased activity of CAT protein

PMID:11742581 PMID:23041170

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G6pc1

glucose-6-phosphatase catalytic subunit 1

increases activity

aluminum phosphide results in increased activity of G6PC1 protein

NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729

G6pdx

glucose-6-phosphate dehydrogenase X-linked

decreases activity

aluminum phosphide results in decreased activity of G6PD protein

NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800

Pfkl

phosphofructokinase, liver, B-type

decreases activity

aluminum phosphide results in decreased activity of PFKL protein

NCBI chr10:77,822,781...77,845,641
Ensembl chr10:77,822,781...77,845,917

Pygl

liver glycogen phosphorylase

increases activity

aluminum phosphide results in increased activity of PYGL protein

NCBI chr12:70,237,589...70,274,457
Ensembl chr12:70,237,585...70,278,262

Ren1

renin 1 structural

increases activity

aluminum phosphide results in increased activity of REN protein

PMID:2200784

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

Tnni3

troponin I, cardiac 3

multiple interactions
increases expression

Taurine inhibits the reaction [aluminum phosphide results in increased expression of TNNI3 protein]

PMID:34139304

NCBI chr 7:4,521,304...4,526,228
Ensembl chr 7:4,521,304...4,527,228

aluminium sulfate (anhydrous)

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Adam9

ADAM metallopeptidase domain 9

decreases expression

aluminum sulfate results in decreased expression of ADAM9 mRNA

NCBI chr 8:25,439,627...25,507,138
Ensembl chr 8:25,439,627...25,506,943

App

amyloid beta precursor protein

affects expression
increases expression

aluminum sulfate affects the expression of APP protein
aluminum sulfate results in increased expression of APP mRNA

PMID:10721010 PMID:15961160

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

Casp1

caspase 1

multiple interactions

[Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein]

PMID:23430110 PMID:24158569

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

Ctsb

cathepsin B

increases expression

aluminum sulfate results in increased expression of CTSB protein

PMID:24158569

NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372

Daxx

Fas death domain-associated protein

increases expression

aluminum sulfate results in increased expression of DAXX mRNA

NCBI chr17:34,128,379...34,134,564
Ensembl chr17:34,128,388...34,134,564

Gata2

GATA binding protein 2

decreases expression

aluminum sulfate results in decreased expression of GATA2 mRNA

NCBI chr 6:88,170,873...88,184,014
Ensembl chr 6:88,170,873...88,184,014

Gtf2h1

general transcription factor II H, polypeptide 1

decreases expression

aluminum sulfate results in decreased expression of GTF2H1 mRNA

NCBI chr 7:46,445,518...46,473,224
Ensembl chr 7:46,445,527...46,473,224

insulin-like growth factor 1

increases secretion

aluminum sulfate results in increased secretion of IGF1 protein

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

Igf2

insulin-like growth factor 2

increases secretion

aluminum sulfate results in increased secretion of IGF2 mRNA; aluminum sulfate results in increased secretion of IGF2 protein

NCBI chr 7:142,204,505...142,220,566
Ensembl chr 7:142,204,503...142,220,553

Igfbp3

insulin-like growth factor binding protein 3

decreases secretion

aluminum sulfate results in decreased secretion of IGFBP3 protein

NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923

Igfbp4

insulin-like growth factor binding protein 4

decreases secretion

aluminum sulfate results in decreased secretion of IGFBP4 protein

NCBI chr11:98,930,820...98,943,481
Ensembl chr11:98,932,070...98,945,218

Il18

interleukin 18

increases expression

aluminum sulfate results in increased expression of IL18 protein

PMID:16100009

NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140

interleukin 1 beta

increases expression
multiple interactions

aluminum sulfate results in increased expression of IL1B mRNA
[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Sodium inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of IL1B protein]; NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]

PMID:15961160 PMID:23430110 PMID:24158569

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

Map2

microtubule-associated protein 2

multiple interactions

aluminum sulfate inhibits the reaction [Excitatory Amino Acid Agents results in increased metabolism of MAP2 protein]

PMID:10428068

NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742

Mapt

microtubule-associated protein tau

increases phosphorylation

aluminum sulfate results in increased phosphorylation of MAPT protein

PMID:11388372

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

Mir146

microRNA 146

multiple interactions

[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA; Curcumin inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; Resveratrol analog inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]

PMID:22099153

NCBI chr11:43,265,224...43,265,288
Ensembl chr11:43,265,224...43,265,288

Mtf1

metal response element binding transcription factor 1

decreases expression

aluminum sulfate results in decreased expression of MTF1 mRNA

NCBI chr 4:124,696,342...124,743,593
Ensembl chr 4:124,695,897...124,743,593

Nefl

neurofilament, light polypeptide

decreases expression

aluminum sulfate results in decreased expression of NEFL mRNA

NCBI chr14:68,321,312...68,326,544
Ensembl chr14:68,321,312...68,326,544

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

increases expression
multiple interactions

aluminum sulfate results in increased expression of NFKB1 mRNA
[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]

PMID:15961160 PMID:22099153

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

Nlrp3

NLR family, pyrin domain containing 3

multiple interactions

NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]

PMID:24158569

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

Nos1

nitric oxide synthase 1, neuronal

decreases expression

aluminum sulfate results in decreased expression of NOS1 protein

PMID:10428068

NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905

P2rx1

purinergic receptor P2X, ligand-gated ion channel, 1

decreases expression

aluminum sulfate results in decreased expression of P2RX1 mRNA

NCBI chr11:72,889,882...72,906,026
Ensembl chr11:72,889,929...72,906,026

Pla2g4a

phospholipase A2, group IVA (cytosolic, calcium-dependent)

increases expression

aluminum sulfate results in increased expression of PLA2G4A mRNA

NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041

Pml

promyelocytic leukemia

multiple interactions

[Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of PML protein

PMID:23430110

NCBI chr 9:58,124,462...58,157,077
Ensembl chr 9:58,125,359...58,157,069

prostaglandin-endoperoxide synthase 2

increases expression

aluminum sulfate results in increased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

Pycard

PYD and CARD domain containing

multiple interactions

PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]

PMID:24158569

NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]

PMID:22099153

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

Robo2

roundabout guidance receptor 2

decreases expression

aluminum sulfate results in decreased expression of ROBO2 mRNA

NCBI chr16:73,688,725...75,244,331
Ensembl chr16:73,688,727...74,208,713

Syn1

synapsin I

decreases expression

aluminum sulfate results in decreased expression of SYN1 mRNA

NCBI chr X:20,726,750...20,787,157
Ensembl chr X:20,726,750...20,787,243

Syp

synaptophysin

decreases expression

aluminum sulfate results in decreased expression of SYP mRNA

NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495

aluminium trifluoride

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Arf6

ADP-ribosylation factor 6

increases activity

aluminum fluoride results in increased activity of ARF6 protein

PMID:16280360

NCBI chr12:69,418,924...69,422,754
Ensembl chr12:69,418,924...69,420,557

Cd3e

CD3 antigen, epsilon polypeptide

increases phosphorylation
multiple interactions

aluminum fluoride results in increased phosphorylation of CD3E protein
Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3E protein]

PMID:2824607

NCBI chr 9:44,910,033...44,920,961
Ensembl chr 9:44,910,038...44,920,925

Cd3g

CD3 antigen, gamma polypeptide

multiple interactions
increases phosphorylation

Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3G protein]

PMID:2824607

NCBI chr 9:44,880,870...44,891,729
Ensembl chr 9:44,880,870...44,891,729

Cd79a

CD79A antigen (immunoglobulin-associated alpha)

increases phosphorylation

aluminum fluoride results in increased phosphorylation of CD79A protein

PMID:8559152

NCBI chr 7:24,596,922...24,601,283
Ensembl chr 7:24,596,806...24,601,622

Cd79b

CD79B antigen

increases phosphorylation

aluminum fluoride results in increased phosphorylation of CD79B protein

PMID:8559152

NCBI chr11:106,202,167...106,205,388
Ensembl chr11:106,202,167...106,205,588

Herc1

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

affects localization

aluminum fluoride affects the localization of HERC1 protein

PMID:14960311

NCBI chr 9:66,257,694...66,416,057
Ensembl chr 9:66,257,732...66,416,057

Igf2

insulin-like growth factor 2

increases expression

aluminum fluoride results in increased expression of IGF2 mRNA; aluminum fluoride results in increased expression of IGF2 protein

PMID:11996908

NCBI chr 7:142,204,505...142,220,566
Ensembl chr 7:142,204,503...142,220,553

Igfbp4

insulin-like growth factor binding protein 4

decreases expression

aluminum fluoride results in decreased expression of IGFBP4 mRNA; aluminum fluoride results in decreased expression of IGFBP4 protein

PMID:11996908

NCBI chr11:98,930,820...98,943,481
Ensembl chr11:98,932,070...98,945,218

Igfbp5

insulin-like growth factor binding protein 5

increases expression

aluminum fluoride results in increased expression of IGFBP5 mRNA; aluminum fluoride results in increased expression of IGFBP5 protein

PMID:11996908

NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043

Lyn

LYN proto-oncogene, Src family tyrosine kinase

increases phosphorylation

aluminum fluoride results in increased phosphorylation of LYN protein

PMID:8559152

NCBI chr 4:3,676,865...3,791,612
Ensembl chr 4:3,678,115...3,813,122

Plcb1

phospholipase C, beta 1

multiple interactions

PLCB1 protein promotes the reaction [aluminum fluoride results in increased abundance of Inositol Phosphates]

PMID:11377826

NCBI chr 2:134,628,084...135,317,178
Ensembl chr 2:134,627,987...135,317,178

aluminium(0)

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

angiotensin I converting enzyme

decreases activity

Aluminum results in decreased activity of ACE protein

PMID:12008977

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

Ache

acetylcholinesterase

multiple interactions
decreases activity

PMID:15266904 PMID:23354609 PMID:24486960 PMID:29170048 PMID:37415728

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

Acly

ATP citrate lyase

multiple interactions

Aluminum results in increased expression of and results in increased activity of ACLY protein

NCBI chr11:100,367,178...100,418,826
Ensembl chr11:100,367,179...100,418,826

Aco1

aconitase 1

decreases activity

Aluminum results in decreased activity of ACO1 protein

PMID:10806405

NCBI chr 4:40,143,265...40,199,009
Ensembl chr 4:40,143,081...40,198,338

Aco2

aconitase 2, mitochondrial

decreases activity
multiple interactions

PMID:12470706 PMID:16906525 PMID:19010380

NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334

Alb

albumin

affects binding

ALB protein binds to Aluminum

PMID:14507469

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

Alox5

arachidonate 5-lipoxygenase

multiple interactions
increases expression

PMID:27368151

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

Alpl

alkaline phosphatase, liver/bone/kidney

multiple interactions

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

Apob

apolipoprotein B

increases expression

Aluminum results in increased expression of APOB protein

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

App

amyloid beta precursor protein

affects binding
multiple interactions
increases expression
increases cleavage

PMID:12039845 PMID:16308480 PMID:16724269 PMID:16928369 PMID:16942756 More...

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

Atxn3

ataxin 3

affects folding
multiple interactions

Aluminum affects the folding of ATXN3 protein polymorphism
Aluminum promotes the reaction [ATXN3 protein polymorphism binds to ATXN3 protein polymorphism]

PMID:17300980

NCBI chr12:101,885,160...101,928,139
Ensembl chr12:101,885,160...101,924,505

BCL2-associated X protein

affects response to substance
multiple interactions

PMID:20385067 PMID:31945389 PMID:34547296

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

Bbox1

gamma-butyrobetaine hydroxylase 1

multiple interactions
decreases expression

PMID:21439360

NCBI chr 2:110,094,401...110,145,158
Ensembl chr 2:110,093,042...110,144,905

B cell leukemia/lymphoma 2

multiple interactions

PMID:31945389 PMID:34547296

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

BCL2-like 1

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2L1 protein

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

bone gamma carboxyglutamate protein

multiple interactions
decreases secretion

PMID:9626627 PMID:34547296

NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771

caspase 12

multiple interactions

[aluminum chloride results in increased abundance of Aluminum] which results in increased expression of CASP12 mRNA

NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032

caspase 3

increases expression
multiple interactions

PMID:21972528 PMID:34547296 PMID:37415728

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

Casp9

caspase 9

multiple interactions

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

Casr

calcium-sensing receptor

multiple interactions

PMID:10231437

NCBI chr16:36,310,947...36,382,605
Ensembl chr16:36,314,058...36,382,503

catalase

decreases activity
multiple interactions

PMID:15526171 PMID:17709913 PMID:24486960 PMID:34547296 PMID:37415728

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

Cdh1

cadherin 1

multiple interactions

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

Chat

choline acetyltransferase

decreases expression
decreases activity
multiple interactions

PMID:16724269 PMID:16928369

NCBI chr14:32,130,160...32,187,866
Ensembl chr14:32,130,160...32,187,946

collagen, type I, alpha 1

multiple interactions

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

Crp

C-reactive protein, pentraxin-related

multiple interactions

[Zinc co-treated with Aluminum] results in increased expression of CRP protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of CRP protein

PMID:27816692

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

C-X-C motif chemokine ligand 15

increases expression

Aluminum analog results in increased expression of CXCL8 mRNA

PMID:23724284

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

Cycs

cytochrome c, somatic

multiple interactions

NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518

Daxx

Fas death domain-associated protein

increases expression

Aluminum results in increased expression of DAXX mRNA

PMID:16308480

NCBI chr17:34,128,379...34,134,564
Ensembl chr17:34,128,388...34,134,564

Drd1

dopamine receptor D1

multiple interactions

Aluminum inhibits the reaction [SCH 23390 binds to DRD1 protein]

NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724

Drd2

dopamine receptor D2

multiple interactions

Aluminum inhibits the reaction [3-N-methylspiperone binds to DRD2 protein]

NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477

Eno2

enolase 2, gamma neuronal

decreases activity

Aluminum results in decreased activity of ENO2 protein

PMID:11860913

NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636

Epor

erythropoietin receptor

affects expression

Aluminum affects the expression of EPOR protein

PMID:15777837

NCBI chr 9:21,870,193...21,874,915
Ensembl chr 9:21,870,193...21,874,802

Esr1

estrogen receptor 1 (alpha)

multiple interactions

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

Esr2

estrogen receptor 2 (beta)

multiple interactions

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

coagulation factor VIII

affects folding
multiple interactions

Aluminum affects the folding of F8 protein
[Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein

PMID:15349964

NCBI chr X:74,213,950...74,426,342
Ensembl chr X:74,216,321...74,426,221

Fh1

fumarate hydratase 1

multiple interactions

Aluminum results in decreased expression of and results in decreased activity of FH protein

PMID:16906525

NCBI chr 1:175,428,944...175,453,201
Ensembl chr 1:175,427,940...175,453,201

Fos

FBJ osteosarcoma oncogene

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein]

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G6pdx

glucose-6-phosphate dehydrogenase X-linked

increases activity

Aluminum results in increased activity of G6PD protein

PMID:16572710 PMID:16979867

NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800

Gfap

glial fibrillary acidic protein

increases expression
multiple interactions

PMID:16545059 PMID:31363819

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

Gnai1

G protein subunit alpha i1

decreases expression

Aluminum results in decreased expression of GNAI1 protein

NCBI chr 5:18,470,133...18,565,411
Ensembl chr 5:18,470,133...18,565,353

Gnai2

G protein subunit alpha i2

decreases expression

Aluminum results in decreased expression of GNAI2 protein

NCBI chr 9:107,491,324...107,512,542
Ensembl chr 9:107,491,324...107,512,566

Gnaq

guanine nucleotide binding protein, alpha q polypeptide

increases response to substance

GNAQ protein results in increased susceptibility to Aluminum

PMID:15068510

NCBI chr19:16,110,048...16,365,884
Ensembl chr19:16,110,195...16,364,827

Gpd1

glycerol-3-phosphate dehydrogenase 1 (soluble)

multiple interactions

Aluminum results in increased expression of and results in increased activity of GPD1 protein

NCBI chr15:99,615,468...99,622,895
Ensembl chr15:99,615,396...99,622,886

Gpx1

glutathione peroxidase 1

decreases activity
multiple interactions

Aluminum results in decreased activity of GPX1 protein
Vitamin E inhibits the reaction [Aluminum results in decreased activity of GPX1 protein]

PMID:17709913

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

Gsr

glutathione reductase

decreases expression
multiple interactions

Aluminum results in decreased expression of GSR protein
Plant Extracts inhibits the reaction [Aluminum results in decreased expression of GSR protein]

PMID:24486960

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

Hif1a

hypoxia inducible factor 1, alpha subunit

increases localization

Aluminum results in increased localization of HIF1A protein

NCBI chr12:73,948,098...73,994,328
Ensembl chr12:73,948,149...73,994,304

Hk1

hexokinase 1

multiple interactions
decreases activity

Meclofenoxate inhibits the reaction [Aluminum results in decreased activity of HK1 protein]

PMID:16969689

NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687

Idh1

isocitrate dehydrogenase 1 (NADP+), soluble

decreases activity

Aluminum results in decreased activity of IDH1 protein

NCBI chr 1:65,197,775...65,225,638
Ensembl chr 1:65,197,775...65,225,659

Idh2

isocitrate dehydrogenase 2 (NADP+), mitochondrial

decreases activity

Aluminum results in decreased activity of IDH2 protein

NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140

Ifnb1

interferon beta 1, fibroblast

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IFNB1 mRNA]

NCBI chr 4:88,440,253...88,441,083
Ensembl chr 4:88,440,262...88,441,011

insulin-like growth factor 1

multiple interactions

Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]

PMID:14745455

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

Il12b

interleukin 12b

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL12B mRNA]

NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860

interleukin 1 beta

multiple interactions
increases expression

PMID:16545059 PMID:27368151 PMID:29170048

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

interleukin 4

increases expression

Aluminum results in increased expression of IL4 mRNA

PMID:16630673

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

interleukin 6

multiple interactions
increases expression

PMID:27368151 PMID:27816692 PMID:29170048 PMID:37415728

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

Jun

jun proto-oncogene

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein]

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

Klk1

kallikrein 1

multiple interactions

Aluminum binds to and results in decreased activity of KLK1 protein

PMID:15558947

NCBI chr 7:43,874,784...43,879,046
Ensembl chr 7:43,874,784...43,879,042

Litaf

LPS-induced TN factor

multiple interactions

[Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of LITAF mRNA

PMID:17408380

NCBI chr16:10,777,137...10,810,985
Ensembl chr16:10,777,139...10,884,021

Lonrf2

LON peptidase N-terminal domain and ring finger 2

decreases expression

Aluminum results in decreased expression of LONRF2 mRNA

NCBI chr 1:38,832,750...38,875,768
Ensembl chr 1:38,832,726...38,875,792

Map1lc3b

microtubule-associated protein 1 light chain 3 beta

multiple interactions

NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499

Mapk3

mitogen-activated protein kinase 3

multiple interactions

[Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein

PMID:16728372

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

Mapt

microtubule-associated protein tau

increases phosphorylation
multiple interactions

PMID:17662457 PMID:29170048

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

Mir21a

microRNA 21a

multiple interactions

[Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR21 mRNA

NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984

Mir30d

microRNA 30d

multiple interactions

[Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR30D mRNA

NCBI chr15:68,213,057...68,213,138
Ensembl chr15:68,213,057...68,213,138

Mir322

microRNA 322

multiple interactions

[Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR424 mRNA

NCBI chr X:52,143,132...52,143,226
Ensembl chr X:52,143,132...52,143,226

matrix metallopeptidase 2

increases expression

Aluminum results in increased expression of MMP2 protein

PMID:16052892

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

Mmp7

matrix metallopeptidase 7

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP7 mRNA

NCBI chr 9:7,692,091...7,699,586
Ensembl chr 9:7,692,091...7,699,586

Mmp9

matrix metallopeptidase 9

increases expression
multiple interactions

Aluminum results in increased expression of MMP9 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP9 mRNA

PMID:16052892 PMID:32437896

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

Mpo

myeloperoxidase

increases expression

Aluminum results in increased expression of MPO protein

PMID:17402216

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

Mtr

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions

PMID:14745455 PMID:26989453

NCBI chr13:12,196,217...12,273,090
Ensembl chr13:12,197,598...12,272,999

nuclear factor, erythroid derived 2, like 2

multiple interactions

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

Nos2

nitric oxide synthase 2, inducible

multiple interactions

PMID:16728372 PMID:23690655

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

Nrg1

neuregulin 1

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]

NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825
Ensembl chr 8:32,304,579...33,374,825

Ogdh

oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)

multiple interactions
increases activity

Aluminum results in decreased expression of and results in decreased activity of OGDH protein
Aluminum results in increased activity of OGDH protein

PMID:10806405 PMID:16906525

NCBI chr11:6,241,597...6,309,094
Ensembl chr11:6,241,633...6,306,642

Oprd1

opioid receptor, delta 1

multiple interactions

[Enkephalin, D-Penicillamine (2,5)- binds to and results in increased activity of OPRD1 protein] which results in decreased abundance of Aluminum

PMID:7477890

NCBI chr 4:131,834,980...131,872,042
Ensembl chr 4:131,838,037...131,871,797

Pck1

phosphoenolpyruvate carboxykinase 1, cytosolic

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of PCK1 protein

NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066

proliferating cell nuclear antigen

multiple interactions

[aluminum chloride results in increased abundance of Aluminum] which results in decreased expression of PCNA mRNA

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

Pink1

PTEN induced putative kinase 1

multiple interactions

NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618

Pklr

pyruvate kinase liver and red blood cell

increases activity

Aluminum results in increased activity of PKLR protein

NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091

Plcd1

phospholipase C, delta 1

increases expression

Aluminum results in increased expression of PLCD1 protein

PMID:10814511

NCBI chr 9:118,900,595...118,922,570
Ensembl chr 9:118,900,595...118,922,570

Prkn

parkin RBR E3 ubiquitin protein ligase

multiple interactions

NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

PMID:16928369 PMID:23690655

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

Pth

parathyroid hormone

multiple interactions

[TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein

PMID:10978387

NCBI chr 7:112,984,783...112,987,879
Ensembl chr 7:112,984,787...112,987,777

Rcvrn

recoverin

multiple interactions

[APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA

PMID:21298039

NCBI chr11:67,586,152...67,594,181
Ensembl chr11:67,586,152...67,594,159

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

Rpl37

ribosomal protein L37

decreases expression

Aluminum results in decreased expression of RPL37 mRNA; Aluminum results in decreased expression of RPL37 protein

NCBI chr15:5,146,127...5,148,626
Ensembl chr15:5,146,127...5,148,622

S100b

S100 protein, beta polypeptide, neural

increases expression
multiple interactions

Aluminum results in increased expression of S100B protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of S100B protein]

PMID:16545059

NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993

Scgb1a1

secretoglobin, family 1A, member 1

decreases expression

Aluminum results in decreased expression of SCGB1A1 protein

PMID:16052892 PMID:16099050

NCBI chr19:9,061,006...9,065,320
Ensembl chr19:9,061,000...9,065,322

Slc2a1

solute carrier family 2 (facilitated glucose transporter), member 1

increases expression

Aluminum results in increased expression of SLC2A1 protein

NCBI chr 4:118,965,942...118,994,527
Ensembl chr 4:118,965,908...118,995,180

Snai1

snail family zinc finger 1

multiple interactions

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein

NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734

Snca

synuclein, alpha

affects response to substance

SNCA protein affects the susceptibility to Aluminum

PMID:23106139

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

Sod2

superoxide dismutase 2, mitochondrial

decreases activity

Aluminum results in decreased activity of SOD2 protein

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

Sqstm1

sequestosome 1

multiple interactions

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

Tfrc

transferrin receptor

decreases expression
affects uptake

Aluminum results in decreased expression of TFRC mRNA
TFRC protein affects the uptake of Aluminum

PMID:9630424 PMID:11068183

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

transforming growth factor, beta 1

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of TGFB1 mRNA

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

tumor necrosis factor

increases expression
multiple interactions

PMID:16545059 PMID:17408380 PMID:23690655 PMID:27368151 PMID:29170048 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

Trf

transferrin

multiple interactions
increases uptake
affects binding

PMID:1375080 PMID:2039817 PMID:2308257 PMID:8782865 PMID:10978387 More...

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

Tubb3

tubulin, beta 3 class III

multiple interactions

[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of TUBB3 protein

PMID:31363819

NCBI chr 8:124,138,292...124,148,754
Ensembl chr 8:124,138,163...124,148,754

Txn2

thioredoxin 2

multiple interactions

[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of TXN2 protein

NCBI chr15:77,799,251...77,813,194
Ensembl chr15:77,799,247...77,813,206

Uba52

ubiquitin A-52 residue ribosomal protein fusion product 1

decreases expression

Aluminum results in decreased expression of UBA52 mRNA; Aluminum results in decreased expression of UBA52 protein

NCBI chr 8:70,960,913...70,963,067
Ensembl chr 8:70,960,913...70,963,451

Vegfa

vascular endothelial growth factor A

multiple interactions

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VEGFA protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of and results in increased secretion of VEGFA protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased secretion of VEGFA protein

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

Vim

vimentin

multiple interactions

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein

NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637

Xdh

xanthine dehydrogenase

increases activity

Aluminum results in increased activity of XDH protein

PMID:11787993

NCBI chr17:74,190,890...74,257,369
Ensembl chr17:74,190,890...74,257,191

boric acid

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

angiotensin I converting enzyme

multiple interactions

boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein]

PMID:28544013

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

Acta2

actin alpha 2, smooth muscle, aorta

decreases expression

boric acid results in decreased expression of ACTA2 protein

NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990

Adipoq

adiponectin, C1Q and collagen domain containing

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

Agt

angiotensinogen

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

Akt1

thymoma viral proto-oncogene 1

increases expression

boric acid results in increased expression of AKT1 mRNA

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

Arg1

arginase, liver

decreases activity

boric acid results in decreased activity of ARG1 protein

PMID:21232540

NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382

Atf4

activating transcription factor 4

increases expression

boric acid results in increased expression of ATF4 mRNA; boric acid results in increased expression of ATF4 protein

PMID:25425213 PMID:27587023

NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742

Atf6

activating transcription factor 6

multiple interactions

boric acid results in increased cleavage of and affects the localization of ATF6 protein

NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340

BCL2-associated X protein

decreases expression
multiple interactions

boric acid results in decreased expression of BAX mRNA
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein

PMID:31368021 PMID:33137424

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

B cell leukemia/lymphoma 2

increases expression
multiple interactions

boric acid results in increased expression of BCL2 mRNA
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein

PMID:31368021 PMID:33137424

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

Calr

calreticulin

increases expression

boric acid results in increased expression of CALR mRNA

NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563

caspase 3

multiple interactions
decreases expression

boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA]
boric acid results in decreased expression of CASP3 mRNA

PMID:31368021 PMID:31823256

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

catalase

multiple interactions
decreases activity

[boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein]
boric acid results in decreased activity of CAT protein
boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein]

PMID:26184899 PMID:29913234 PMID:30997025 PMID:31823256

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

Ccnd1

cyclin D1

increases expression
multiple interactions

boric acid results in increased expression of CCND1 mRNA
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

Cebpa

CCAAT/enhancer binding protein alpha

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]

NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353

Cebpb

CCAAT/enhancer binding protein beta

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]

NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338

Col1a2

collagen, type I, alpha 2

affects expression

boric acid affects the expression of COL1A2 mRNA

PMID:24704097

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

Csf2

colony stimulating factor 2 (granulocyte-macrophage)

increases expression

boric acid results in increased expression of CSF2 protein

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

Csf3

colony stimulating factor 3 (granulocyte)

increases expression

boric acid results in increased expression of CSF3 protein

NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455

Cst3

cystatin C

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of CST3 protein]

NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612

Ctnnb1

catenin beta 1

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]

NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573

Ddit3

DNA-damage inducible transcript 3

decreases expression

boric acid results in decreased expression of DDIT3 mRNA; boric acid results in decreased expression of DDIT3 protein

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

Des

desmin

affects expression

boric acid affects the expression of DES mRNA

NCBI chr 1:75,336,936...75,345,223
Ensembl chr 1:75,336,973...75,345,223

Dvl2

dishevelled segment polarity protein 2

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]

NCBI chr11:69,891,418...69,900,935
Ensembl chr11:69,891,421...69,903,127

Edem1

ER degradation enhancer, mannosidase alpha-like 1

increases expression

boric acid results in increased expression of EDEM1 mRNA

NCBI chr 6:108,800,984...108,836,317
Ensembl chr 6:108,805,602...108,836,317

Eif2ak3

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229

Eif2s1

eukaryotic translation initiation factor 2, subunit 1 alpha

increases phosphorylation
multiple interactions

boric acid results in increased phosphorylation of EIF2S1 protein
EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]

PMID:25425213 PMID:27587023 PMID:30196486

NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784

Fabp4

fatty acid binding protein 4, adipocyte

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]

NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636

Fasn

fatty acid synthase

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]

NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373

Fgf2

fibroblast growth factor 2

multiple interactions

boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

Fgf7

fibroblast growth factor 7

increases expression

boric acid results in increased expression of FGF7 protein

NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105

Fn1

fibronectin 1

affects expression
increases expression

boric acid affects the expression of FN1 mRNA
boric acid results in increased expression of FN1 mRNA

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

Gapdh

glyceraldehyde-3-phosphate dehydrogenase

decreases expression

boric acid results in decreased expression of GAPDH protein

NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430

Gas6

growth arrest specific 6

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]

NCBI chr 8:13,515,374...13,544,535
Ensembl chr 8:13,515,374...13,544,490

Gck

glucokinase

increases expression

boric acid results in increased expression of GCK mRNA

NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081

Gclc

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

boric acid results in increased expression of GCLC mRNA
EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

Gpt

glutamic pyruvic transaminase, soluble

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

Havcr1

hepatitis A virus cellular receptor 1

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein]

NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405

Herpud1

homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1

increases expression

boric acid results in increased expression of HERPUD1 mRNA

NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005

Hmox1

heme oxygenase 1

increases expression

boric acid results in increased expression of HMOX1 mRNA

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

Hoxa6

homeobox A6

affects expression

boric acid affects the expression of HOXA6 mRNA

PMID:12749385

NCBI chr 6:52,181,838...52,185,652
Ensembl chr 6:52,183,268...52,185,702

Hoxc6

homeobox C6

affects expression

boric acid affects the expression of HOXC6 mRNA

PMID:12749385

NCBI chr15:102,906,658...102,920,314
Ensembl chr15:102,906,689...102,920,313

Hspa5

heat shock protein 5

increases expression

boric acid results in increased expression of HSPA5 mRNA; boric acid results in increased expression of HSPA5 protein

PMID:25425213 PMID:27587023

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

Ifng

interferon gamma

multiple interactions

[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IFNG mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein]

PMID:29913234 PMID:30368975 PMID:32179172 PMID:33137424

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

Il10

interleukin 10

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL10 mRNA

PMID:30997025 PMID:32179172

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

Il18

interleukin 18

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of IL18 protein]

NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140

interleukin 1 beta

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL1B mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]

PMID:29913234 PMID:30368975 PMID:30997025 PMID:32179172

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

Il2

interleukin 2

multiple interactions

NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108

interleukin 4

increases expression
multiple interactions

boric acid results in increased expression of IL4 mRNA
[boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein

PMID:31368021 PMID:33137424

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

interleukin 6

multiple interactions

boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL6 mRNA

PMID:28285642 PMID:30997025 PMID:32179172

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

Ins1

insulin I

increases expression

boric acid results in increased expression of INS1 mRNA

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

Ins2

insulin II

multiple interactions
increases expression

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid results in increased expression of INS2 mRNA

PMID:28285642 PMID:31368021

NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118

Klf5

Kruppel-like transcription factor 5

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]

NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472

Lama5

laminin, alpha 5

increases expression

boric acid results in increased expression of LAMA5 mRNA

NCBI chr 2:179,818,166...179,867,652
Ensembl chr 2:179,818,166...179,867,652

Lep

leptin

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

Lipe

lipase, hormone sensitive

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]

NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135

Mapk1

mitogen-activated protein kinase 1

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

Mapk3

mitogen-activated protein kinase 3

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

matrix metallopeptidase 2

decreases expression

boric acid results in decreased expression of MMP2 protein

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

Myh1

myosin, heavy polypeptide 1, skeletal muscle, adult

affects expression

boric acid affects the expression of MYH1 mRNA

NCBI chr11:67,090,922...67,115,401
Ensembl chr11:67,090,878...67,115,401

Myod1

myogenic differentiation 1

affects expression
decreases expression

boric acid affects the expression of MYOD1 mRNA
boric acid results in decreased expression of MYOD1 protein

NCBI chr 7:46,025,898...46,028,516
Ensembl chr 7:46,025,898...46,028,523

Myog

myogenin

affects expression

boric acid affects the expression of MYOG mRNA

NCBI chr 1:134,217,742...134,220,286
Ensembl chr 1:134,217,727...134,220,286

nuclear factor, erythroid derived 2, like 2

affects localization
multiple interactions

boric acid affects the localization of NFE2L2 protein
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions
affects expression

boric acid affects the reaction [Formaldehyde results in increased expression of NFKB1 mRNA]
boric acid affects the expression of NFKB1 mRNA

PMID:31823256

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

Nos2

nitric oxide synthase 2, inducible

multiple interactions

boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

Nqo1

NAD(P)H dehydrogenase, quinone 1

increases expression

boric acid results in increased expression of NQO1 mRNA

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

proliferating cell nuclear antigen

increases expression
multiple interactions

boric acid results in increased expression of PCNA protein
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA

PMID:17943231 PMID:33137424

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

Pdx1

pancreatic and duodenal homeobox 1

increases expression

boric acid results in increased expression of PDX1 mRNA

NCBI chr 5:147,206,907...147,212,658
Ensembl chr 5:147,206,769...147,212,658

Pparg

peroxisome proliferator activated receptor gamma

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

Ppp1r15a

protein phosphatase 1, regulatory subunit 15A

increases expression

boric acid results in increased expression of PPP1R15A mRNA; boric acid results in increased expression of PPP1R15A protein

NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692

prostaglandin-endoperoxide synthase 2

multiple interactions

boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein]

PMID:29913234 PMID:30368975

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

Runx2

runt related transcription factor 2

affects expression

boric acid affects the expression of RUNX2 mRNA

PMID:24704097

NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684

Slc2a2

solute carrier family 2 (facilitated glucose transporter), member 2

increases expression

boric acid results in increased expression of SLC2A2 mRNA

NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508

Slc2a4

solute carrier family 2 (facilitated glucose transporter), member 4

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]

NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014

Slc4a2

solute carrier family 4 (anion exchanger), member 2

increases expression

boric acid results in increased expression of SLC4A2 mRNA

PMID:22576912

NCBI chr 5:24,628,939...24,645,945
Ensembl chr 5:24,628,835...24,645,948

Slc4a3

solute carrier family 4 (anion exchanger), member 3

increases expression

boric acid results in increased expression of SLC4A3 mRNA

PMID:22576912

NCBI chr 1:75,522,688...75,536,075
Ensembl chr 1:75,522,910...75,538,816

Sparc

secreted acidic cysteine rich glycoprotein

affects expression

boric acid affects the expression of SPARC mRNA

PMID:24704097

NCBI chr11:55,284,985...55,310,906
Ensembl chr11:55,285,326...55,314,009

Srebf1

sterol regulatory element binding transcription factor 1

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]

NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407

Syvn1

synovial apoptosis inhibitor 1, synoviolin

decreases expression

boric acid results in decreased expression of SYVN1 mRNA

NCBI chr19:6,096,586...6,103,748
Ensembl chr19:6,096,606...6,103,742

transforming growth factor, beta 1

increases expression

boric acid results in increased expression of TGFB1 protein
boric acid results in increased expression of TGFB1 mRNA

PMID:27206737 PMID:31368021

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

tumor necrosis factor

multiple interactions
decreases expression
increases secretion
increases expression

boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
boric acid results in decreased expression of TNF mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of TNF mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]
boric acid results in increased secretion of TNF protein
boric acid results in increased expression of TNF mRNA

PMID:9618283 PMID:18755394 PMID:29913234 PMID:30368975 PMID:30997025 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

Tnfrsf1a

tumor necrosis factor receptor superfamily, member 1a

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]

NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447

Trp53

transformation related protein 53

decreases expression

boric acid results in decreased expression of TRP53 mRNA

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

Xbp1

X-box binding protein 1

increases expression

boric acid results in increased expression of XBP1 mRNA

NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893

boric acids

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Ggt1

gamma-glutamyltransferase 1

decreases activity

Boric Acids analog results in decreased activity of GGT1 protein

PMID:6149445

NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034

Muc1

mucin 1, transmembrane

decreases expression

Boric Acids results in decreased expression of MUC1 mRNA

PMID:21060261

NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688

Muc16

mucin 16

decreases expression

Boric Acids results in decreased expression of MUC16 mRNA

PMID:21060261

NCBI chr 9:18,406,741...18,586,117
Ensembl chr 9:18,406,751...18,585,826

boron atom

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Atrnl1

attractin like 1

increases expression

Boron results in increased expression of ATRNL1 mRNA

NCBI chr19:57,599,248...58,121,775
Ensembl chr19:57,599,466...58,121,775

BCL2-associated X protein

multiple interactions

[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

B cell leukemia/lymphoma 2

multiple interactions

[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

bone gamma carboxyglutamate protein

increases expression

Boron results in increased expression of BGLAP mRNA

NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771

Bmp7

bone morphogenetic protein 7

increases expression

Boron results in increased expression of BMP7 mRNA

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

caspase 3

increases expression

Boron results in increased expression of CASP3 protein modified form

PMID:23462526

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

catalase

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; Boron inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]

PMID:30997025 PMID:36419211

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

Ccnd1

cyclin D1

decreases expression

Boron results in decreased expression of CCND1 protein

PMID:23462526

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

collagen, type I, alpha 1

increases expression

Boron results in increased expression of COL1A1 mRNA

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

Crp

C-reactive protein, pentraxin-related

multiple interactions

Boron inhibits the reaction [Dietary Fats results in increased expression of CRP mRNA]

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

Cst3

cystatin C

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of CST3 protein]

NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612

Gpt

glutamic pyruvic transaminase, soluble

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

Havcr1

hepatitis A virus cellular receptor 1

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein]

NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405

Ifng

interferon gamma

multiple interactions

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

Il10

interleukin 10

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA]

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

Il18

interleukin 18

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of IL18 protein]

NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140

interleukin 1 beta

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA]

PMID:30997025 PMID:36419211

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

Il2

interleukin 2

multiple interactions

NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108

interleukin 4

multiple interactions

[boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

interleukin 6

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

Lep

leptin

multiple interactions

Boron inhibits the reaction [Dietary Fats results in increased expression of LEP mRNA]

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

proliferating cell nuclear antigen

multiple interactions

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

Ppara

peroxisome proliferator activated receptor alpha

multiple interactions

Boron inhibits the reaction [Dietary Fats results in decreased expression of PPAR mRNA]

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

Sod1

superoxide dismutase 1, soluble

multiple interactions

Boron inhibits the reaction [Dietary Fats results in decreased activity of SOD1 protein]

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

tumor necrosis factor

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA]

PMID:30997025 PMID:36419211

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

bortezomib

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

1110059E24Rik

RIKEN cDNA 1110059E24 gene

increases expression

Bortezomib results in increased expression of C9ORF85 mRNA

NCBI chr19:21,574,677...21,630,155
Ensembl chr19:21,558,566...21,630,340

1810037I17Rik

RIKEN cDNA 1810037I17 gene

decreases expression

Bortezomib results in decreased expression of C4ORF3 mRNA

NCBI chr 3:122,718,046...122,719,843
Ensembl chr 3:122,717,852...122,719,833

4933434E20Rik

RIKEN cDNA 4933434E20 gene

decreases expression

Bortezomib results in decreased expression of C1ORF43 mRNA

NCBI chr 3:89,958,941...89,969,754
Ensembl chr 3:89,958,943...89,970,648
Ensembl chr 3:89,958,943...89,970,648

Abca2

ATP-binding cassette, sub-family A member 2

decreases expression

Bortezomib results in decreased expression of ABCA2 mRNA

NCBI chr 2:25,318,611...25,338,556
Ensembl chr 2:25,318,715...25,338,552

Abcb1a

ATP-binding cassette, sub-family B member 1A

multiple interactions
decreases expression
decreases activity

[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein
Bortezomib results in decreased activity of ABCB1 protein

PMID:25576094 PMID:30482226 PMID:33775688 PMID:34915026

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

Abcc1

ATP-binding cassette, sub-family C member 1

decreases expression
multiple interactions

Bortezomib results in decreased expression of ABCC1 mRNA
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein

PMID:20977926 PMID:33775688

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

Abcc2

ATP-binding cassette, sub-family member 2

increases expression

Bortezomib results in increased expression of ABCC2 mRNA

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

Abcc4

ATP-binding cassette, sub-family C member 4

decreases expression

Bortezomib results in decreased expression of ABCC4 mRNA

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

Abhd16a

abhydrolase domain containing 16A

increases expression

Bortezomib results in increased expression of ABHD16A mRNA

NCBI chr17:35,308,210...35,321,963
Ensembl chr17:35,308,239...35,321,963

Abhd2

abhydrolase domain containing 2

increases expression

Bortezomib results in increased expression of ABHD2 mRNA

NCBI chr 7:78,923,002...79,015,257
Ensembl chr 7:78,922,947...79,015,256

Abi1

abl interactor 1

increases expression

Bortezomib results in increased expression of ABI1 mRNA

NCBI chr 2:22,830,085...22,930,207
Ensembl chr 2:22,830,085...22,930,253

Abl1

c-abl oncogene 1, non-receptor tyrosine kinase

multiple interactions

[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein]

PMID:15039284 PMID:17495969 PMID:21195056

NCBI chr 2:31,578,256...31,697,105
Ensembl chr 2:31,578,388...31,694,239

angiotensin I converting enzyme

multiple interactions

[Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form

PMID:20454656

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

Acot7

acyl-CoA thioesterase 7

decreases expression

Bortezomib results in decreased expression of ACOT7 mRNA

NCBI chr 4:152,258,872...152,356,312
Ensembl chr 4:152,262,591...152,356,312

Adam10

a disintegrin and metallopeptidase domain 10

decreases expression

Bortezomib results in decreased expression of ADAM10 mRNA

NCBI chr 9:70,586,133...70,687,511
Ensembl chr 9:70,586,279...70,687,511

Adm

adrenomedullin

multiple interactions
decreases expression

Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA

PMID:20471514

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

Aff1

AF4/FMR2 family, member 1

increases expression

Bortezomib results in increased expression of AFF1 mRNA

NCBI chr 5:103,840,307...104,003,188
Ensembl chr 5:103,840,240...104,003,188

Aff4

AF4/FMR2 family, member 4

increases expression

Bortezomib results in increased expression of AFF4 mRNA

NCBI chr11:53,240,807...53,312,657
Ensembl chr11:53,241,660...53,312,657

Afg2a

AFG2 AAA ATPase homolog A

increases expression

Bortezomib results in increased expression of AFG2A mRNA

NCBI chr 3:37,474,052...37,633,245
Ensembl chr 3:37,474,045...37,633,245

Ager

advanced glycosylation end product-specific receptor

increases expression
multiple interactions

Bortezomib results in increased expression of AGER mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA]

PMID:35121005

NCBI chr17:34,816,545...34,819,911
Ensembl chr17:34,816,836...34,819,910

Agk

acylglycerol kinase

decreases expression

Bortezomib results in decreased expression of AGK mRNA

NCBI chr 6:40,302,010...40,378,723
Ensembl chr 6:40,302,106...40,373,696

Agrn

agrin

decreases expression

Bortezomib results in decreased expression of AGRN mRNA

NCBI chr 4:156,249,747...156,281,997
Ensembl chr 4:156,249,747...156,281,945

Agtpbp1

ATP/GTP binding protein 1

increases expression

Bortezomib results in increased expression of AGTPBP1 mRNA

NCBI chr13:59,597,348...59,705,184
Ensembl chr13:59,593,556...59,733,041

Agtrap

angiotensin II, type I receptor-associated protein

decreases expression

Bortezomib results in decreased expression of AGTRAP mRNA

NCBI chr 4:148,161,518...148,172,521
Ensembl chr 4:148,161,518...148,172,488

AI837181

expressed sequence AI837181

decreases expression

Bortezomib results in decreased expression of C11ORF68 mRNA

NCBI chr19:5,475,172...5,477,345
Ensembl chr19:5,475,172...5,477,341

Aifm1

apoptosis-inducing factor, mitochondrion-associated 1

affects localization
multiple interactions

Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein

PMID:12893773 PMID:16024631

NCBI chr X:47,563,821...47,602,440
Ensembl chr X:47,563,821...47,602,440

Aifm2

apoptosis-inducing factor, mitochondrion-associated 2

increases expression

Bortezomib results in increased expression of AIFM2 mRNA

NCBI chr10:61,551,042...61,575,474
Ensembl chr10:61,551,042...61,575,039

Aim2

absent in melanoma 2

increases expression

Bortezomib results in increased expression of AIM2 mRNA

NCBI chr 1:173,177,105...173,293,606
Ensembl chr 1:173,178,445...173,293,606

Airim

AFG2 interacting ribosome maturation factor

increases expression

Bortezomib results in increased expression of AIRIM mRNA

NCBI chr 4:124,830,777...124,838,454
Ensembl chr 4:124,830,841...124,838,449

Akr1b1

aldo-keto reductase family 1 member B

increases expression

Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein

NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413

Akr1b10

aldo-keto reductase family 1, member B10

increases expression

Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein

NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885

Akr1c18

aldo-keto reductase family 1, member C18

increases expression

Bortezomib results in increased expression of AKR1C3 mRNA

NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653

Akr1c20

aldo-keto reductase family 1, member C20

multiple interactions
increases expression

[Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA
Bortezomib results in increased expression of AKR1C1 mRNA

PMID:21215737 PMID:25913414

NCBI chr13:4,536,855...4,573,353
Ensembl chr13:4,536,848...4,573,344

Akr1c21

aldo-keto reductase family 1, member C21

affects expression

Bortezomib affects the expression of AKR1C2 mRNA

NCBI chr13:4,624,074...4,636,542
Ensembl chr13:4,624,074...4,636,540

Akr7a5

aldo-keto reductase family 7, member A5

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA

PMID:25522274

NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737

Akt1

thymoma viral proto-oncogene 1

multiple interactions
decreases expression
decreases activity

[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein

PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 More...

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

Aldh18a1

aldehyde dehydrogenase 18 family, member A1

decreases expression

Bortezomib results in decreased expression of ALDH18A1 mRNA

NCBI chr19:40,538,701...40,576,907
Ensembl chr19:40,538,701...40,576,907

Aldh5a1

aldhehyde dehydrogenase family 5, subfamily A1

decreases expression

Bortezomib results in decreased expression of ALDH5A1 mRNA

NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644

Aldh6a1

aldehyde dehydrogenase family 6, subfamily A1

decreases expression

Bortezomib results in decreased expression of ALDH6A1 mRNA

NCBI chr12:84,477,491...84,497,798
Ensembl chr12:84,477,491...84,497,778

Alox12

arachidonate 12-lipoxygenase

increases response to substance

ALOX12 gene SNP results in increased susceptibility to Bortezomib

PMID:20864405

NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179

Anapc11

anaphase promoting complex subunit 11

decreases expression

Bortezomib results in decreased expression of ANAPC11 mRNA

PMID:17659339

NCBI chr11:120,489,247...120,499,024
Ensembl chr11:120,489,247...120,499,024

Anapc5

anaphase-promoting complex subunit 5

decreases expression
increases expression

Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA

PMID:17895889 PMID:20977926

NCBI chr 5:122,925,522...122,960,402
Ensembl chr 5:122,925,522...122,959,402

Ankrd9

ankyrin repeat domain 9

increases expression

Bortezomib results in increased expression of ANKRD9 mRNA

NCBI chr12:110,942,854...110,945,516
Ensembl chr12:110,941,787...110,945,474

Ano10

anoctamin 10

increases expression

Bortezomib results in increased expression of ANO10 mRNA

NCBI chr 9:122,004,940...122,123,508
Ensembl chr 9:122,004,940...122,123,489

Ap1s1

adaptor protein complex AP-1, sigma 1

decreases expression

Bortezomib results in decreased expression of AP1S1 mRNA

NCBI chr 5:137,063,847...137,074,962
Ensembl chr 5:137,063,847...137,074,989

Ap2a1

adaptor-related protein complex 2, alpha 1 subunit

decreases expression

Bortezomib results in decreased expression of AP2A1 mRNA

NCBI chr 7:44,549,797...44,578,914
Ensembl chr 7:44,549,797...44,578,920

Apobr

apolipoprotein B receptor

decreases expression

Bortezomib results in decreased expression of APOBR mRNA

NCBI chr 7:126,184,092...126,188,297
Ensembl chr 7:126,184,114...126,188,284

Apol9a

apolipoprotein L 9a

decreases expression

Bortezomib results in decreased expression of APOL4 mRNA

NCBI chr15:77,287,989...77,295,280
Ensembl chr15:77,287,989...77,295,335

Apool

apolipoprotein O-like

increases expression

Bortezomib results in increased expression of APOOL mRNA

NCBI chr X:111,221,049...111,282,452
Ensembl chr X:111,221,031...111,282,452

Aqp3

aquaporin 3

increases expression

Bortezomib results in increased expression of AQP3 mRNA

NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183

androgen receptor

multiple interactions

Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein]

PMID:25752796 PMID:30818834

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

Arf6

ADP-ribosylation factor 6

increases expression

Bortezomib results in increased expression of ARF6 mRNA

NCBI chr12:69,418,924...69,422,754
Ensembl chr12:69,418,924...69,420,557

Arfgap1

ADP-ribosylation factor GTPase activating protein 1

decreases expression

Bortezomib results in decreased expression of ARFGAP1 mRNA

NCBI chr 2:180,608,290...180,624,319
Ensembl chr 2:180,609,018...180,624,319

Arhgap1

Rho GTPase activating protein 1

decreases expression

Bortezomib results in decreased expression of ARHGAP1 mRNA

NCBI chr 2:91,480,463...91,502,670
Ensembl chr 2:91,480,205...91,502,671

Arhgdia

Rho GDP dissociation inhibitor alpha

decreases expression

Bortezomib results in decreased expression of ARHGDIA mRNA

NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450

Arid3b

AT-rich interaction domain 3B

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA

PMID:25522274

NCBI chr 9:57,697,636...57,744,130
Ensembl chr 9:57,697,636...57,744,076

Arl4c

ADP-ribosylation factor-like 4C

decreases expression

Bortezomib results in decreased expression of ARL4C mRNA

NCBI chr 1:88,625,947...88,629,913
Ensembl chr 1:88,600,847...88,629,943

Arl8a

ADP-ribosylation factor-like 8A

increases expression

Bortezomib results in increased expression of ARL8A mRNA

NCBI chr 1:135,074,572...135,084,007
Ensembl chr 1:135,074,562...135,084,007

Arrb1

arrestin, beta 1

decreases expression

Bortezomib results in decreased expression of ARRB1 mRNA

NCBI chr 7:99,184,356...99,255,979
Ensembl chr 7:99,184,673...99,255,978

Asap1

ArfGAP with SH3 domain, ankyrin repeat and PH domain1

decreases expression

Bortezomib results in decreased expression of ASAP1 mRNA

NCBI chr15:63,958,704...64,254,922
Ensembl chr15:63,958,706...64,254,768

Ate1

arginyltransferase 1

increases expression

Bortezomib results in increased expression of ATE1 mRNA

NCBI chr 7:129,993,219...130,122,349
Ensembl chr 7:129,993,223...130,122,099

Atf2

activating transcription factor 2

multiple interactions
increases phosphorylation
increases expression

pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA

PMID:12393500 PMID:20977926

NCBI chr 2:73,646,853...73,723,094
Ensembl chr 2:73,646,853...73,722,983

Atf3

activating transcription factor 3

increases response to substance
multiple interactions
increases expression

ATF3 results in increased susceptibility to Bortezomib
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein

PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274

NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236

Atf4

activating transcription factor 4

multiple interactions
increases expression
decreases response to substance

1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib

PMID:15509775 PMID:16928686 PMID:20022965

NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742

Atf5

activating transcription factor 5

increases expression

Bortezomib results in increased expression of ATF5 mRNA

PMID:17898295

NCBI chr 7:44,461,680...44,466,082
Ensembl chr 7:44,461,680...44,466,082

Atg5

autophagy related 5

multiple interactions

ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]

PMID:22842577

NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287

Atm

ataxia telangiectasia mutated

multiple interactions
increases cleavage

[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein]

PMID:12393500

NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040

Atp1a3

ATPase, Na+/K+ transporting, alpha 3 polypeptide

decreases expression

Bortezomib results in decreased expression of ATP1A3 mRNA

NCBI chr 7:24,677,592...24,705,502
Ensembl chr 7:24,677,592...24,705,383

Atp2a1

ATPase, Ca++ transporting, cardiac muscle, fast twitch 1

multiple interactions
affects response to substance

ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib

PMID:25576094

NCBI chr 7:126,045,032...126,062,245
Ensembl chr 7:126,045,030...126,062,280

Atp6v0e

ATPase, H+ transporting, lysosomal V0 subunit E

increases expression

Bortezomib results in increased expression of ATP6V0E1 mRNA

NCBI chr17:26,895,370...26,918,621
Ensembl chr17:26,882,205...26,918,621

B2m

beta-2 microglobulin

decreases expression

Bortezomib results in decreased expression of B2M protein

PMID:17204182

NCBI chr 2:121,978,168...121,983,563
Ensembl chr 2:121,978,167...121,983,564

B3gnt2

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2

decreases expression

Bortezomib results in decreased expression of B3GNT2 mRNA

NCBI chr11:22,784,739...22,810,336
Ensembl chr11:22,709,738...22,810,961

B4galt6

UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6

increases expression

Bortezomib results in increased expression of B4GALT6 mRNA

NCBI chr18:20,817,656...20,879,461
Ensembl chr18:20,817,656...20,879,461

Bag3

BCL2-associated athanogene 3

increases expression

Bortezomib results in increased expression of BAG3 mRNA

PMID:15509775 PMID:17659339 PMID:20471514

NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705

Bak1

BCL2-antagonist/killer 1

multiple interactions
increases expression

[nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein

PMID:12902978 PMID:17326159 PMID:20850924

NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983

Bard1

BRCA1 associated RING domain 1

increases response to substance

BARD1 mutant form results in increased susceptibility to Bortezomib

PMID:25522274

NCBI chr 1:71,066,690...71,142,300
Ensembl chr 1:71,066,657...71,142,305

BCL2-associated X protein

multiple interactions
increases expression

[Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein

PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

Bbc3

BCL2 binding component 3

increases expression

Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein

PMID:17898295 PMID:20051518

NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130

Bbln

bublin coiled coil protein

decreases expression

Bortezomib results in decreased expression of BBLN mRNA

NCBI chr 2:32,269,120...32,271,877
Ensembl chr 2:32,267,109...32,271,950

BC005537

cDNA sequence BC005537

increases expression

Bortezomib results in increased expression of C6ORF62 mRNA

NCBI chr13:24,985,640...24,996,882
Ensembl chr13:24,985,640...25,000,180

B cell leukemia/lymphoma 2

multiple interactions
decreases expression
increases cleavage
increases expression

[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein

PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 More...

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

Bcl2a1b

B cell leukemia/lymphoma 2 related protein A1b

multiple interactions
increases expression

[romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein

PMID:18223231 PMID:20051518

NCBI chr 9:89,081,326...89,089,891
Ensembl chr 9:89,081,262...89,089,880

BCL2-like 1

multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance

[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib

PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 More...

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

Bcl2l11

BCL2 like 11

multiple interactions
increases expression
increases activity
increases response to substance

[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib

PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 More...

NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467

Bcl2l2

BCL2-like 2

increases expression

Bortezomib results in increased expression of BCL2L2 mRNA

PMID:18928586

NCBI chr14:55,120,900...55,125,691
Ensembl chr14:55,120,834...55,125,691
Ensembl chr14:55,120,834...55,125,691

Bcl3

B cell leukemia/lymphoma 3

multiple interactions
decreases expression

[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA

PMID:20471514 PMID:20977926

NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695

Bcl6

B cell leukemia/lymphoma 6

increases expression

Bortezomib results in increased expression of BCL6 mRNA

NCBI chr16:23,780,058...23,807,602
Ensembl chr16:23,783,802...23,807,602

Bcl7a

B cell CLL/lymphoma 7A

decreases expression

Bortezomib results in decreased expression of BCL7A mRNA

NCBI chr 5:123,482,511...123,512,146
Ensembl chr 5:123,481,897...123,513,055

Bcr

BCR activator of RhoGEF and GTPase

decreases expression

Bortezomib results in decreased expression of BCR mRNA

NCBI chr10:74,896,384...75,020,755
Ensembl chr10:74,896,424...75,020,753

Becn1

beclin 1, autophagy related

multiple interactions
decreases response to substance

BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib

PMID:22842577

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

Bid

BH3 interacting domain death agonist

increases cleavage
multiple interactions

Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]

PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 More...

NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814

Bik

BCL2-interacting killer

increases response to substance
increases expression
increases activity

BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein

PMID:16446371 PMID:18566236

NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835

Bin1

bridging integrator 1

increases expression

Bortezomib results in increased expression of BIN1 mRNA

PMID:17659339

NCBI chr18:32,509,671...32,568,793
Ensembl chr18:32,510,283...32,568,790

Birc2

baculoviral IAP repeat-containing 2

decreases expression
multiple interactions

Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein

PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231

NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065

Birc3

baculoviral IAP repeat-containing 3

decreases expression
increases expression
multiple interactions

Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA

PMID:17626072 PMID:24085292 PMID:25522274

NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187

Birc5

baculoviral IAP repeat-containing 5

decreases expression
multiple interactions
increases expression

Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein]
Bortezomib results in increased expression of BIRC5 protein

PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 More...

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

Birc7

baculoviral IAP repeat-containing 7

multiple interactions
decreases expression

arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA]

PMID:21867610

NCBI chr 2:180,570,402...180,575,803
Ensembl chr 2:180,570,816...180,575,803

Blk

B lymphoid kinase

decreases expression

Bortezomib results in decreased expression of BLK mRNA

NCBI chr14:63,610,286...63,654,636
Ensembl chr14:63,610,285...63,654,486

Blvrb

biliverdin reductase B

increases expression

Bortezomib results in increased expression of BLVRB mRNA

NCBI chr 7:27,147,403...27,165,406
Ensembl chr 7:27,147,403...27,165,569

Bnip3

BCL2/adenovirus E1B interacting protein 3

increases expression

Bortezomib results in increased expression of BNIP3 protein

PMID:20110775

NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248

Brca1

breast cancer 1, early onset

decreases expression
increases response to substance
decreases ubiquitination
multiple interactions

Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 mutant form results in increased susceptibility to Bortezomib
Bortezomib results in decreased ubiquitination of BRCA1 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
BRCA1 gene mutant form results in increased susceptibility to Bortezomib
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]

PMID:21917757 PMID:25522274

NCBI chr11:101,379,587...101,442,808
Ensembl chr11:101,379,590...101,442,781

Brca2

breast cancer 2, early onset

decreases expression
multiple interactions

Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA

PMID:21917757 PMID:25913414

NCBI chr 5:150,445,759...150,493,612
Ensembl chr 5:150,446,095...150,493,794

Brcc3

BRCA1/BRCA2-containing complex, subunit 3

decreases expression

Bortezomib results in decreased expression of BRCC3 mRNA

NCBI chr X:74,460,234...74,499,307
Ensembl chr X:74,460,234...74,497,607

Brf2

BRF2, RNA polymerase III transcription initiation factor 50kDa subunit

increases expression

Bortezomib results in increased expression of BRF2 mRNA

NCBI chr 8:27,613,367...27,618,743
Ensembl chr 8:27,613,392...27,618,708

Bsdc1

BSD domain containing 1

increases expression

Bortezomib results in increased expression of BSDC1 mRNA

NCBI chr 4:129,355,472...129,382,291
Ensembl chr 4:129,355,374...129,382,291

Caap1

caspase activity and apoptosis inhibitor 1

increases expression

Bortezomib results in increased expression of CAAP1 mRNA

NCBI chr 4:94,388,318...94,445,033
Ensembl chr 4:94,388,318...94,445,033

Cacna1h

calcium channel, voltage-dependent, T type, alpha 1H subunit

decreases degradation

Bortezomib results in decreased degradation of CACNA1H protein

PMID:30552955

NCBI chr17:25,593,259...25,655,308
Ensembl chr17:25,593,259...25,652,757

Calr

calreticulin

multiple interactions
increases expression

[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]

PMID:30482226

NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563

Capn15

calpain 15

decreases expression

Bortezomib results in decreased expression of CAPN15 mRNA

NCBI chr17:26,177,338...26,204,753
Ensembl chr17:26,177,338...26,204,770

Car9

carbonic anhydrase 9

decreases expression

Bortezomib results in decreased expression of CA9 protein

PMID:16061869

NCBI chr 4:43,507,026...43,513,729
Ensembl chr 4:43,506,966...43,513,729

Card9

caspase recruitment domain family, member 9

multiple interactions

[arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA

PMID:20471514

NCBI chr 2:26,242,199...26,250,957
Ensembl chr 2:26,242,188...26,250,930

caspase 12

increases cleavage

Bortezomib results in increased cleavage of CASP12 protein

PMID:15509775 PMID:16357177

NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032

Casp2

caspase 2

multiple interactions
increases response to substance
increases cleavage